Details of the Researcher

PHOTO

Hirotaka Ishida
Section
Tohoku University Hospital
Job title
Assistant Professor
e-Rad No.
00807703

Research History 10

  • 2026/04 - Present
    東北大学病院　総合外科　病院講師

  • 2022/04 - 2026/03
    Tohoku University Hospital　Department of Surgery

  • 2020/09 - 2022/03
    山形県立新庄病院　外科・乳腺外科　副部長

  • 2018/04 - 2020/08
    Griffith University　Molecular Pathology

  • 2018/02 - 2018/03
    Tohoku University　Tohoku Medical Megabank Organization

  • 2017/12 - 2018/01
    南三陸病院　外科　医員

  • 2017/04 - 2017/11
    東北大学病院　移植・再建・内視鏡外科　医員

  • 2013/04 - 2017/03
    東北大学大学院 医学系研究科　先進外科学分野　大学院生

  • 2011/04 - 2013/03
    気仙沼市立病院　外科　後期研修医

  • 2009/04 - 2011/03
    気仙沼市立病院　初期研修医

Show all Show first 5

Education 2

  • Tohoku University　Graduate School of Medicine

    2013/04 - 2017/03

  • Yamagata University　Faculty of Medicine　School of Medicine

    2003/04 - 2009/03

Professional Memberships 8

  • 麻酔科標榜医

  • 日本癌治療認定医機構 がん治療認定医

  • 日本胸部外科学会 JATS-NEXTコアメンバー（食道）

  • 日本消化器内視鏡学会 消化器内視鏡専門医・東北支部評議員

  • 日本消化器病学会 消化器病専門医・東北支部評議員

  • 日本食道学会 食道科認定医・選挙評議員

  • 日本消化器外科学会 消化器外科専門医・消化器がん外科治療認定医

  • 日本外科学会 外科専門医・指導医

︎Show all ︎Show first 5

Research Interests 7

  • 食道癌 / 診断マーカー / 超硫黄分子 / 呼気凝集液

  • Esophageal cancer / Biomarker

  • Esophageal cancer / Oligometastasis

  • CRP/Procalcitonin

  • p16/HPV

  • 食道神経内分泌癌

  • 食道癌

Research Areas 3

  • Life sciences / Human pathology /

  • Life sciences / Human pathology /

  • Life sciences / Digestive surgery /

Awards 2

  1. Poster of Distinction

    2025/09　Treatment Strategies and Long-term Outcomes for Patients with Oligometastasis in Esophageal Squamous Cell Carcinoma after Radical Esophagectomy

  2. 優秀演題賞

    2024/07　侵襲とサイトカイン研究会　低侵襲食道切除後・プロカルシトニンの感染性合併症/予後予測マーカーとしての意義

Papers 63

  1. Clinical and Prognostic Impacts of Heme Oxygenase-1 Expression in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Chemotherapy. Peer-reviewed

    Atsushi Kunimitsu, Hirotaka Ishida, Hironobu Sasano, Hiroyuki Oshikiri, Naoto Ujiie, Yohei Ozawa, Hiroshi Okamoto, Chiaki Sato, Yusuke Taniyama, Fumiyoshi Fujishima, Takashi Suzuki, Takashi Kamei

    The Tohoku journal of experimental medicine　2026/07/30

    DOI： 10.1620/tjem.2026.J088 　

  2. Utility of multimodal deep learning model to diagnose lymph node metastasis in esophageal cancer using computed tomography and positron emission tomography images. Peer-reviewed

    Yasuharu Shinozaki, Hirotaka Ishida, Tomofumi Kaneno, Eichi Takaya, Tomoya Kobayashi, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Takuya Ueda, Takashi Kamei

    Surgery today　56　(4)　462-469　2026/04

    Publisher: Springer Science and Business Media LLC

    DOI： 10.1007/s00595-025-03152-5 　

    ISSN： 0941-1291

    eISSN： 1436-2813

    More details Close

    Abstract Purpose This study aimed to assess the performance of a deep learning model using multimodal imaging for detecting lymph node metastasis in esophageal cancer in comparison to expert assessments. Methods A retrospective analysis was performed for 521 lymph nodes from 167 patients with esophageal cancer who underwent esophagectomy. Deep learning models were developed based on multimodal imaging, including non-contrast-enhanced computed tomography, contrast-enhanced computed tomography, and positron emission tomography imaging. The diagnostic performance was evaluated and compared with expert assessments using a receiver operating characteristic curve analysis. Results The area under the receiver operating characteristic curve values for the deep learning model were 0.81 with multimodal imaging, 0.73 with non-contrast-enhanced computed tomography, 0.72 with contrast-enhanced computed tomography, and 0.75 with positron emission tomography were calculated. The area under the curve of the deep learning model (0.81) demonstrated diagnostic performance comparable to that of experienced experts (area under the curve, 0.84; P = 0.62, DeLong’s test). Conclusion The multimodal deep learning model using computed tomography and positron emission tomography demonstrated performance comparable to that of experts in diagnosing the presence of lymph node metastasis, a key prognostic factor in esophageal cancer, suggesting its potential clinical utility.

  3. Prognostic significance of postoperative serum C-reactive protein levels after minimally invasive esophagectomy for esophageal cancer Peer-reviewed

    Hirotaka Ishida, Toshiaki Fukutomi, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Jun Takahashi, Iku Sasaki-Higashimoto, Michiaki Unno, Takashi Kamei

    General Thoracic and Cardiovascular Surgery　2026/02

    DOI： 10.1007/s11748-025-02213-3 　

  4. Prevalence and distribution of human papillomavirus type 16 in esophageal squamous cell carcinoma and its association with p16INK4A expression: A large-scale study in Japan. International-journal Peer-reviewed

    Kaiyuan Jiang, Hirotaka Ishida, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Yuto Yamazaki, Hironobu Sasano, Michiaki Unno, Takashi Suzuki, Takashi Kamei

    Human Pathology　166　105983-105983　2025/11/12

    DOI： 10.1016/j.humpath.2025.105983 　

    More details Close

    The infection rate of human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC) varies widely (0 %-88.9 %), and the diagnostic utility of p16INK4A as a surrogate marker remains controversial. Moreover, the distribution of HPV infection in ESCC has not been previously investigated. Patients with ESCC who underwent esophagectomy without neoadjuvant therapy between 2007 and 2022 were included in this study. Three formalin-fixed, paraffin-embedded blocks (oral side, tumor, and esophagogastric junction (EGJ)) were collected. p16INK4A expression was assessed by immunohistochemistry (positivity defined as a labeling index of ≥10 %), whereas HPV type 16 DNA was detected by polymerase chain reaction. The distribution of HPV distribution was also assessed. In total, 158 patients were analyzed. p16INK4A was detected in 19.0 % (30/158) and HPV DNA in 3.8 % (6/158) of tumor samples. The sensitivity and positive predictive value of p16INK4A immunohistochemistry for detecting HPV DNA were 100 % and 20.0 %, respectively. HPV DNA was also detected in 3.6 % (5/137) of the oral side and 2.7 % (4/146) of EGJ samples. Infectious mapping revealed a random distribution pattern across the three anatomical regions. This large-scale study demonstrated a low prevalence of HPV infection in ESCC and indicated that p16INK4A immunohistochemistry may aid in reducing the risk of missing patients with HPV-positive tumors. Notably, the random-like distribution of HPV DNA across the three anatomical sites suggests partial viral clearance by the host immune response. These findings underscore the potential for false-negative results in biopsy specimens obtained from non-infected regions in otherwise HPV-positive patients.

  5. Treatment strategies and long-term outcomes for patients with oligometastasis in esophageal squamous cell carcinoma after radical esophagectomy. Peer-reviewed

    Hirotaka Ishida, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Ryohei Ando, Jun Takahashi, Michiaki Unno, Takashi Kamei

    Esophagus　2025/04/17

    DOI： 10.1007/s10388-025-01126-7 　

    More details Close

    BACKGROUND: Advancements in esophageal cancer treatment have not substantially reduced the high recurrence rate and poor survival outcomes following esophagectomy; however, patients with oligometastasis may benefit from aggressive local treatments. METHODS: We performed curative esophagectomy in 714 patients with esophageal squamous cell carcinoma between 2007 and 2022. In total, 206 patients with recurrent lesions were enrolled in this study. Oligometastasis was defined as ≤ 5 lesions in a single organ or lymph node station. Treatments included surgery, chemoradiotherapy (CRT), chemotherapy, and radiotherapy. Disease-specific survival (DSS) was defined as the time from the initial recurrence to disease-related death or the last observation. RESULTS: Among the patients, 109 had oligometastasis, most commonly in the lymph nodes (N = 84), followed by the lung (N = 8) and liver (N = 7). The DSS rate in patients with oligometastasis (5-year DSS: 37.5%) was significantly higher than that in patients with multiple metastases (3.3%) (P < 0.001). Metastatic lesions are more likely to be oligometastatic when a disease-free interval (DFI) is prolonged. In the oligometastasis cohort, surgery or CRT was associated with significantly improved survival outcomes, particularly among patients with a DFI of less than 9 months. The selection of treatment modalities was significantly influenced by the patient's performance status (PS), with better PS being associated with a greater likelihood of receiving surgery or CRT. CONCLUSION: Aggressive local treatment should be considered for oligometastasis after esophagectomy to improve long-term survival. A good PS after esophagectomy is crucial for the effective treatment of oligometastatic lesions.

  6. Serum C-reactive protein and procalcitonin levels in patients with pneumonia and anastomotic leakage in the postoperative period after esophagectomy. Peer-reviewed

    Hirotaka Ishida, Toshiaki Fukutomi, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Ryohei Ando, Yasuharu Shinozaki, Michiaki Unno, Takashi Kamei

    General Thoracic and Cardiovascular Surgery　2024/07/29

    DOI： 10.1007/s11748-024-02065-3 　

    More details Close

    OBJECTIVE: Despite being a less-invasive procedure, esophagectomy can cause severe infectious complications, such as pneumonia and anastomotic leakage. Herein, we aimed to clarify the inflammatory characteristics of pneumonia/anastomotic leakage after esophagectomy by assessing the difference between the postoperative trends of serum C-reactive protein (CRP) and procalcitonin (PCT) levels in patients with pneumonia/anastomotic leakage using the values on the consecutive postoperative day (POD). METHODS: This study included 439 patients who underwent minimally invasive esophagectomy. Serum CRP and PCT levels were measured on PODs 1-7, 10, and 14. Pneumonia and anastomotic leakage were defined as Clavien-Dindo grades ≥ 2. RESULTS: Pneumonia and anastomotic leakage occurred in 96 and 51 patients, respectively. The CRP and PCT levels peaked on POD 3 (11.6 ± 6.8 mg/dL) and POD 2 (0.69 ± 2.9 ng/mL), respectively. Between PODs 3 and 14, CRP levels were significantly higher in patients with pneumonia and anastomotic leakage than in those without complications (P < 0.001). Between PODs 3 and 14, PCT levels were significantly higher in patients with pneumonia; however, on most PODs, there were no significant differences in PCT levels between patients with and without anastomotic leakage. CONCLUSION: Inflammatory reactions caused by pneumonia may be more intense than those caused by anastomotic leakage after esophagectomy. Postoperative trends in serum CRP and PCT levels may vary depending on the complication type. Pneumonia and anastomotic leakage after esophagectomy can be potentially distinguished by the postoperative trend of PCT values before detailed examinations, such as computed tomography and endoscopy.

  7. Blood flow ratio in the gastric conduit measured by laser Doppler flowmetry: A predictor of anastomotic leakage after esophagectomy Peer-reviewed

    Hirotaka Ishida, Toshiaki Fukutomi, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Yu Onodera, Ken Koseki, Michiaki Unno, Takashi Kamei

    Annals of Gastroenterological Surgery　2024/03

    DOI： 10.1002/AGS3.12754 　

  8. Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer. International-journal Peer-reviewed

    Sharmin Aktar, Farhadul Islam, Tracie Cheng, Sujani Madhurika Kodagoda Gamage, Indra Neil Choudhury, Md Sajedul Islam, Cu Tai Lu, Faysal Bin Hamid, Hirotaka Ishida, Ichiro Abe, Nan Xie, Vinod Gopalan, Alfred K Lam

    Genes　14　(9)　2023/09/16

    DOI： 10.3390/genes14091808 　

    More details Close

    Combination strategies of KRAS inhibition with immunotherapy in treating advanced or recurrent colorectal carcinoma (CRC) may need to be assessed in circulating tumour cells (CTCs) to achieve better clinical outcomes. This study aimed to investigate the genomic variations of KRAS in CTCs and matched CRC tissues and compared mRNA expression of KRAS and CTLA-4 between wild-type and KRAS-mutated CTCs and CRC tissues. Clinicopathological correlations were also compared. Six known mutations of KRAS were identified at both codon 12 and codon 13 (c.35G>T/G12V, c.35G>A7/G12D, c.35G>C/G12A, c.34G>A/G12S, c.38G>C/G13A, and c.38G>A/G13D). Three CTC samples harboured the identified mutations (16.7%; 3/18), while fifteen matched primary tumour tissues (65.2%, 15/23) showed the mutations. CTCs harbouring the KRAS variant were different from matched CRC tissue. All the mutations were heterozygous. Though insignificant, CTLA-4 mRNA expression was higher in patients carrying KRAS mutations. Patients harbouring KRAS mutations in CTCs were more likely to have poorly differentiated tumours (p = 0.039) and with lymph node metastasis (p = 0.027) and perineural invasion (p = 0.014). KRAS mutations in CTCs were also significantly correlated with overall pathological stages (p = 0.027). These findings imply the genetic basis of KRAS with immunotherapeutic target molecules based on a real-time platform. This study also suggests the highly heterogeneous nature of cancer cells, which may facilitate the assessment of clonal dynamics across a single patient's disease.

  9. A diagnostic pitfall; Small cell carcinoma-like features in basaloid squamous cell carcinoma of the esophagus. International-journal Peer-reviewed

    Hirotaka Ishida, Atsuko Kasajima, Takuro Yamauchi, Ryujiro Akaishi, Shunsuke Ueki, Yusuke Taniyama, Fumiyoshi Fujishima, Tomoyuki Koike, Takashi Kamei, Alfred King-Yin Lam, Hironobu Sasano

    Histology and Histopathology　18497-18497　2022/07/21

    DOI： 10.14670/HH-18-497 　

    More details Close

    Esophageal basaloid squamous cell carcinoma may resemble small cell carcinoma biopsy specimens and cause difficulties in pathology diagnosis. We aimed to clarify the clinicopathological significance of small cell carcinoma-like morphologies in basaloid squamous cell carcinoma. Thirty biopsy specimens of esophageal basaloid squamous cell carcinoma were reviewed and compared with 13 matched surgical specimens. Small cell carcinoma-like features, such as diffuse growth, nuclear molding, or nuclear crush artifact, were identified in 80% (24/30) of the biopsies and in 77% (10/13) of the surgery specimens, but in a proportionally much smaller area in the surgical specimens than in the biopsy samples. The presence of a small cell carcinoma-like feature had no impact on patients´ outcome. Immunohistochemically, synaptophysin and chromogranin A were consistently negative, while CD56 was expressed in 42% (10/24) of basaloid squamous cell carcinomas with small cell carcinoma-like features. p16, a highly sensitive marker for small cell carcinoma, was also expressed in 8% (2/24). p40 was expressed in all cases of basaloid squamous cell carcinoma. In conclusion, small cell carcinoma-like features are frequent and conspicuous in biopsies, which are probably caused by exogenous factors such as friction and external pressure that occur in biopsy procedure and in the tumor environment. Small cell carcinoma-like features may lead to a misinterpretation of a true small cell carcinoma, if CD56 is the only neuroendocrine marker expressed. p16 expression may also be detected in basaloid squamous cell carcinoma.

  10. Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma. International-journal Peer-reviewed

    Ken Ito, Hirotaka Ishida, Fumiyoshi Fujishima, Yasuhiro Nakamura, Takuro Konno, Kazue Ise, Shuko Hata, Yohei Ozawa, Yusuke Taniyama, Takashi Kamei, Hironobu Sasano

    Anticancer Research　42　(6)　2875-2882　2022/06

    DOI： 10.21873/anticanres.15769 　

    More details Close

    BACKGROUND/AIM: Murine double minute 2 (MDM2) is well known to inhibit p53 function and its over-expression is associated with poor prognosis in several human malignancies. Nutlin-3, a small-molecule inhibitor of MDM2, exerts antitumor effects on various solid tumors harboring wild-type p53. We aimed to clarify its effects on esophageal cancer. MATERIALS AND METHODS: We first examined the potential antitumor effects of nutlin-3 according to MDM2 status using esophageal carcinoma cell lines (KYSE 170/180). We then immunolocalized MDM2 immunoreactivity in 62 surgical cases of esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy and correlated the findings with clinicopathological variables. RESULTS: MDM2 mRNA expression in KYSE 170 was significantly higher than that in KYSE 180 cells. No significant changes were detected in both cell lines when nutlin-3 was added. However, cell proliferation was significantly decreased in KYSE 170 cells treated with nutlin-3 and cisplatin compared to cisplatin alone but not in KYSE 180. MDM2 immunoreactivity was also significantly associated with poor sensitivity to neoadjuvant chemotherapy in the cases examined. CONCLUSION: The combination of nutlin-3 with chemotherapeutic agents may become a novel therapeutic strategy in esophageal cancer over-expressing MDM2.

  11. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification. International-journal Peer-reviewed

    Hirotaka Ishida, Alfred King-Yin Lam

    Critical Reviews in Oncology/Hematology　172　103648-103648　2022/03/04

    DOI： 10.1016/j.critrevonc.2022.103648 　

    More details Close

    Pancreatic neuroendocrine neoplasms (PanNENs) are the neuroendocrine neoplasms with greatest rate of increase in incidence. Approximately 10% of PanNENs arise as inherited tumour syndromes which include multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 4, von Hippel-Lindau syndrome, neurofibromatosis type1, tuberous sclerosis complex 1/2, Cowden syndrome, and Glucagon cell hyperplasia and neoplasia as well as familial insulinomatosis. In sporadic PanNENs, driver mutations in MEN1, DAXX/ATRX and mTOR pathway genes are associated with development and progression in pancreatic neuroendocrine tumours. The other changes are in VEGF pathway, Notch pathway, germline mutations in MUTYH, CHEK2, BRCA2, PHLDA3 as well as other genetic alterations. On the other hand, pancreatic neuroendocrine carcinomas share similar genetic alterations with ductal adenocarcinomas, e.g., TP53, RB1 or KRAS. In addition, microRNA and changes in immune microenvironment were noted in PanNENs. Updates on these genetic knowledges contribute to the development of management strategies for patients with PanNENs.

  12. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging. International-journal Peer-reviewed

    Alfred King-Yin Lam, Hirotaka Ishida

    Histology and Histopathology　36　(4)　367-382　2021/04

    DOI： 10.14670/HH-18-288 　

    More details Close

    The nomenclature and classification of pancreatic neuroendocrine neoplasms has evolved in the last 15 years based on the advances in knowledge of the genomics, clinical behaviour and response to therapies. The current 2019 World Health Organization classification of pancreatic neuroendocrine neoplasms categorises them into three groups; pancreatic neuroendocrine tumours (PanNETs)(grade 1 grade 2, grade 3), pancreatic neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) based on the mitotic rate, Ki-67 index, morphological differentiation and/or co-existing tissue subtype. PanNETs are also classified into non-functional NET, insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, ACTH-producing NET and serotonin producing NET based on hormone production and clinical manifestations. A portion of the cases were associated with genetic syndromes such as multiple neuroendocrine neoplasia 1 (MEN 1), neurofibromatosis and Von Hippel-Lindau syndrome. In view of the distinctive pathology and clinical behaviour of PanNENs, the current 8th AJCC/UICC staging system has separated prognostic staging grouping for PanNETs from the pancreatic neuroendocrine carcinomas or MiNENs. Pancreatic neuroendocrine carcinomas and MiNENs are staged according to the prognostic stage grouping for exocrine pancreatic carcinoma. The new stage grouping of PanNETs was validated to have survival curves separated between different prognostic groups. This refined histological and staging would lead to appropriate selections of treatment strategies for the patients with pancreatic neuroendocrine neoplasms.

  13. p16 in highly malignant esophageal carcinomas: the correlation with clinicopathological factors and human papillomavirus infection. International-journal Peer-reviewed

    Hirotaka Ishida, Atsuko Kasajima, Fumiyoshi Fujishima, Ryujiro Akaishi, Shunsuke Ueki, Yuto Yamazaki, Yoshiaki Onodera, Xin Gao, Hiroshi Okamoto, Yusuke Taniyama, Takashi Kamei, Hironobu Sasano

    Virchows Archiv : an international journal of pathology　478　(2)　219-229　2021/02

    DOI： 10.1007/s00428-020-02865-x 　

    More details Close

    p16 is generally considered to be a surrogate maker of human papillomavirus (HPV) infection and also a predictive marker of favorable clinical outcome of patients with squamous cell carcinoma of the oropharynx. p16 overexpression is also known to be induced by deregulation of RB1 in neuroendocrine carcinomas. In highly malignant esophageal neoplasms, however, the status of p16 has remained largely unknown. We immunolocalized p16 and Rb1 in 82 surgically resected esophageal high-grade squamous cell carcinomas (46 poorly differentiated and 36 basaloid squamous cell carcinomas) and 15 esophageal small-cell carcinomas in order to clarify the clinical and biological significance of p16. p16 immunoreactivity was detected in 7/82 (9%) high-grade squamous cell carcinomas and 15 (100%) small-cell carcinomas. p16 immunoreactivity was significantly associated with Rb1 protein loss in both groups (P < 0.001). HPV was detected in none of the p16-positive cases examined. Clinical outcome of the p16-positive high-grade squamous cell carcinomas was not different from that of the p16-negative counterparts (P = 0.687) but significantly better than those with the small-cell carcinomas (P = 0.023). p16 was therefore considered to be induced through an inactivation of the RB1 signaling pathway and not through HPV infection in highly malignant esophageal neoplasms. Nevertheless, patients' clinical outcome of these neoplasms significantly differs; therefore, small-cell carcinomas have to be carefully differentiated from other neoplasms. In addition, p16 overexpression is not predictive of favorable clinical outcome in high-grade squamous cell carcinomas of the esophagus.

  14. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. International-journal Peer-reviewed

    Hirotaka Ishida, Alfred King-Yin Lam

    Critical Reviews in Oncology/Hematology　145　102835-102835　2020/01

    DOI： 10.1016/j.critrevonc.2019.102835 　

    More details Close

    There is a recent update in WHO classification of pancreatic neuroendocrine neoplasms (PanNENs). Our aim is to analyse the latest management for patients with PanNENs according to the current classification of these neoplasms. The primary treatment is curative surgery and the surgical procedures depend on size, location, and histopathology of the tumour. Even if tumour has metastases, debulking surgery or resection of the primary lesion could improve the prognosis of these patients. Systemic medication is indicated in patients with unresectable primary and/or distant metastatic lesions. As new antineoplastic agents have been approved in the last decade for the treatment of PanNENs, the clinical outcome is improving. However, the appropriate selection or the effective combination of drugs has not been fully established. To conclude, management of PanNENs depends on various factors and further development of treatment strategies is required for improvement of survival outcome of patients with PanNENs.

  15. Esophageal Carcinosarcoma with Basaloid Squamous Cell Carcinoma: A Case Report and Review of the Literature. Peer-reviewed

    Hirotaka Ishida, Fumiyoshi Fujishima, Yu Onodera, Takuro Konno-Kumagai, Shota Maruyama, Hiroshi Okamoto, Chiaki Sato, Takahiro Heishi, Tadashi Sakurai, Yusuke Taniyama, Takashi Kamei, Hironobu Sasano

    The Tohoku Journal of Experimental Medicine　249　(4)　255-263　2019/12

    DOI： 10.1620/tjem.249.255 　

    More details Close

    Esophageal carcinosarcoma is a rare tumor composed of neoplastic squamous epithelium and sarcomatous spindle cells. The origin of spindle cells remains unknown; however, the majority of sarcomatous components are currently considered to be derived from existing carcinomatous cells via epithelial-mesenchymal transition (EMT). We report a case of esophageal carcinosarcoma harboring basaloid squamous cell carcinoma successfully treated with preoperative chemotherapy. A 78-year-old man complaining dysphagia was diagnosed as esophageal carcinosarcoma. After two courses of preoperative chemotherapy with cisplatin and 5-fluorouracil, curative esophagectomy with lymph node dissection was performed thoracoscopically. Histopathological findings of the resected specimen revealed the mixture of basaloid squamous cell carcinoma and sarcomatous spindle cells. A transitional zone between both components was also detected. As fibrosis was identified around both two components, the findings indicated that both carcinomatous and sarcomatous neoplasms disappeared by preoperative chemotherapy. Final pathological diagnosis was esophageal carcinosarcoma with basaloid squamous cell carcinoma. No recurrent lesions have been detected for 25 months after the surgery. Sarcomatous spindle cells could be derived from the components of basaloid squamous cell carcinoma in our present case due to the presence of histological transition between two components. In addition, the marked immunoreactivity of vimentin (an EMT marker) detected in the tumor cells of basaloid squamous cell carcinoma could be consistent with the concept of monoclonal origin via EMT. The regimen targeting squamous cell carcinoma could also be effective in the treatment of sarcomatous components. Preoperative therapy might achieve the improvement of clinical outcome of patients with esophageal carcinosarcoma.

  16. A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma. International-journal Peer-reviewed

    Hirotaka Ishida, Atsuko Kasajima, Yu Onodera, Takuro Konno, Shota Maruyama, Hiroshi Okamoto, Chiaki Sato, Takahiro Heishi, Tadashi Sakurai, Yusuke Taniyama, Masanobu Takahashi, Fumiyoshi Fujishima, Keiichi Jingu, Chikashi Ishioka, Hironobu Sasano, Takashi Kamei

    Medicine　98　(8)　e14363　2019/02

    DOI： 10.1097/MD.0000000000014363 　

    More details Close

    Esophageal small cell carcinoma (E-SmCC) and basaloid squamous cell carcinomas (BSCCs) are both highly aggressive malignancies, but their detailed differences in clinical behaviors have remained virtually unknown. In addition, treatment strategies of the patients with E-SmCC have not been established. 29 cases of E-SmCC and 39 with BSCC were examined in this study to clarify the clinical features and outcome of the patients with E-SmCC and to compare the findings with those of BSCC. E-SmCCs presented a more advanced status than BSCC (TNM Stage: P = .002). Esophagectomy was performed in 15 small cell carcinoma patients and 14 were treated with non-surgical/systemic therapy. The clinical outcome of the small cell carcinoma cases was significantly worse than those with BSCC (P = .001), but results of a stage-stratified analysis revealed that the Stage I small cell carcinoma patients presented favorable prognosis (3-year survival rate 100%, n = 4). In contrast, among those with Stage II-IV, clinical outcome tended to be better in the systemic therapy group (3-year survival rate 49%, n = 13) than the surgically treated group (3-year survival rate 0%, n = 12). E-SmCC was a more aggressive neoplasm than BSCC. However, early detection could possibly improve the clinical outcome of patients with E-SmCC. Systemic therapy could also benefit the patients with advanced disease (Stage II-IV).

  17. SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis. International-journal Peer-reviewed

    Hirotaka Ishida, Atsuko Kasajima, Takashi Kamei, Tsuyoshi Miura, Naomi Oka, Samaneh Yazdani, Yohei Ozawa, Fumiyoshi Fujishima, Akira Sakurada, Yasuhiro Nakamura, Yoichi Tanaka, Masafumi Kurosumi, Yuichi Ishikawa, Yoshinori Okada, Noriaki Ohuchi, Hironobu Sasano

    Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc　30　(5)　660-671　2017/05

    DOI： 10.1038/modpathol.2016.222 　

    More details Close

    Clinicopathological features and pathogenesis of esophageal small-cell carcinoma remain unclear. We hypothesized common cellular origin and pathogenesis in small-cell carcinoma of esophagus and lung associated with SOX2 overexpression and loss of Rb1. Expression of squamous-basal markers (CK5/6 and p40), glandular markers (CK18 and CEA), SOX2, and Rb1 were evaluated in 15 esophageal small-cell carcinomas, 46 poorly differentiated squamous cell carcinomas, and 88 small-cell lung carcinoma, as well as 16 embryonic esophagus. Esophageal small-cell carcinoma expressed higher levels of glandular markers and lower levels of squamous-basal markers than poorly differentiated squamous cell carcinoma. No significant differences were observed in immunohistochemistry profiles between small-cell carcinoma of the esophagus and the lung. SOX2 expression was high in esophageal small-cell carcinoma (70%±33% of nuclei), small-cell lung carcinoma (70%±26%), and the embryonic esophagus (75%±4%), and it was significantly lower in poorly differentiated squamous cell carcinoma (29%±28%). Rb1 expression was significantly lower in esophageal small-cell carcinoma (0.3%±1%), small-cell lung carcinoma (2%±6%), and the embryonic esophagus (7%±5%), and it was significantly higher in poorly differentiated squamous cell carcinoma (51%±24%). The immunohistochemistry profiles of small-cell carcinoma of the esophagus and the lung are highly similar. The loss of Rb1 function is a key contributor to the pathogenesis of both neoplasms. In addition, SOX2 overexpression observed in esophageal and lung small-cell carcinoma as well as in the embryonic esophagus indicated that esophageal small-cell carcinoma may arise from embryonic-like stem cells in the esophageal epithelium. The two distinct differentiation patterns (neuroendocrine and glandular) of esophageal small-cell carcinoma further support the fact that SOX2 has a pivotal role in the differentiation of pluripotent stem cells into esophageal small-cell carcinoma cells.

  18. Surgical resection and chemoradiotherapy for metachronous pulmonary metastasis of basaloid squamous cell carcinoma of the oesophagus. International-journal Peer-reviewed

    Hirotaka Ishida, Toru Nakano, Fumiyoshi Fujishima, Takashi Kamei, Yusuke Taniyama, Tadashi Sakurai, Chiaki Sato, Toshiaki Fukutomi, Kuroudo Kamiya, Yohei Ozawa, Hironobu Sasano, Noriaki Ohuchi

    International Journal of Surgery Case Reports　17　151-4　2015

    DOI： 10.1016/j.ijscr.2015.11.013 　

    More details Close

    INTRODUCTION: Basaloid squamous cell carcinoma of the oesophagus (BSCCE) is a relatively rare variant of oesophageal malignancy. There are no established treatment strategies for pulmonary metastases of BSCCE. PRESENTATION OF CASE: A 72-year-old man underwent oesophagectomy and subsequently received a pathological diagnosis of stage IIIA (T3N1M0) BSCCE according to Union for International Cancer Control. One year and 5 months later, he underwent partial resection of the right lung because of metastasis of the BSCCE. One year and 6 months after the pulmonary resection, recurrence in the right lung was observed. The patient was treated with concurrent chemoradiotherapy using cisplatin and 5-fluorouracil, and the lesion completely disappeared. The patient is doing well without recurrence 5 years after chemoradiotherapy. DISCUSSION: In our case, the recurrent lesion in the right lung was observed after the pulmonary resection. It is difficult to determine whether the recurrent lesion is solitary or multiple and whether it is a local or pleural metastasis. Therefore, surgical indication must be decided carefully. Systemic chemotherapy or radiotherapy is useful to treat BSCCE metastasis, however, appropriate, but which agents and their regimens are appropriate is not clear. Concurrent chemotherapy using cisplatin and 5-fluorouracil and radiotherapy for pulmonary BSCCE metastases may provide curative therapy and should be considered. CONCLUSION: This report describes a case of recurrent pulmonary metastasis after pulmonary resection of BSCCE metastasis, successfully treated by concurrent chemotherapy and radiotherapy. Further studies are required to establish the indications and efficacy of these therapeutic approaches.

  19. Deep learning model for the prediction of lymph node metastasis in esophageal squamous cell carcinoma using MIP FDG-PET images: a retrospective validation study.

    Hiroki Maruyama, Kentaro Takanami, Eichi Takaya, Shinya Sonobe, Yoshitaka Toyama, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Hirotaka Ishida, Kei Takase, Takashi Kamei

    Japanese journal of radiology　2026/09/18

    DOI： 10.1007/s11604-026-02084-5 　

    More details Close

    PURPOSE: Accurate preoperative diagnosis of lymph node (LN) metastasis in esophageal squamous cell carcinoma (ESCC) is crucial for determining treatment strategies, including organ-sparing therapies. We aimed to develop and validate a deep learning (DL) model using rotational maximum-intensity projection (MIP) 18 F-FDG PET images to improve the prediction of LN metastasis. MATERIALS AND METHODS: This retrospective study included 185 patients with ESCC (146 receiving neoadjuvant chemotherapy) who underwent preoperative imaging using a silicon photomultiplier PET scanner. A convolutional neural network (CNN) was developed using six rotational MIP images (angles from - 60° to 90°). The architecture utilized a ResNet-50 backbone with weight sharing across views. The ground truth for LN metastasis was established via postoperative histopathology, including Grade 3 pathological response as positive. The performance of the model in the test set (n = 36) was compared with that of radiologist reports and SUVmax analysis using the area under the receiver operating characteristic curve (AUC) and diagnostic accuracy. RESULTS: The CNN model achieved an AUC of 0.82 (95% CI 0.57-0.94), which was higher but not significantly different from the SUVmax method (0.77, p > 0.05). Although the differences were not statistically significant (p > 0.05), the CNN model achieved the highest absolute diagnostic accuracy of 86% at the optimal threshold, compared with the SUVmax-based method (67%), the clinical data model (75%), and radiologist reports (69%). Notably, while the CNN model exhibited a lower specificity (75%) than radiologist reports (92%), it demonstrated high sensitivity (92%) compared to radiologist (58%) and SUVmax (63%), effectively serving as a diagnostic safety net. CONCLUSION: Our PET-based CNN model using rotational MIP images demonstrated comparable diagnostic accuracy and higher sensitivity for LN metastasis in ESCC than the conventional methods. This proof-of-concept highlights its potential as a preoperative tool for optimizing treatment selection and minimizing understaging.

  20. Harvest of a pedicled omental flap preserving the right gastroepiploic artery for gastric conduit reconstruction in multistage surgery for aortoesophageal fistula.

    Hiroshi Okamoto, Yusuke Taniyama, Chiaki Sato, Yohei Ozawa, Hirotaka Ishida, Takashi Kamei

    General thoracic and cardiovascular surgery　2026/06/01

    DOI： 10.1007/s11748-026-02317-4 　

    More details Close

    Aortoesophageal fistula is a rare but highly fatal condition. Thoracic endovascular aortic repair has led to improved early outcomes. However, subsequent aortic replacement, esophagectomy, and gastrointestinal reconstruction are required to achieve long-term survival. Conventional pedicled flaps using both gastroepiploic arteries can prevent gastric conduit reconstruction, requiring small or large intestinal substitutes associated with greater surgical invasiveness. We developed the pedicled omental flap technique preserving the right gastroepiploic artery, which enabled simultaneous gastric conduit preparation and omental harvest in a multistage surgery. After a specific interval following esophagectomy, the omental flap was mobilized while preserving right gastroepiploic perfusion, and a gastric conduit was created. Both were evaluated via indocyanine green imaging. The omental flap was delivered into the thoracic cavity for later graft coverage. Meanwhile, the gastric conduit was left in situ for delayed reconstruction. This method reduced invasiveness and facilitated staged treatment of aortoesophageal fistula with improved surgical flexibility.

  21. Radiation-Based Multimodal Strategies for Esophageal Squamous Cell Carcinoma: From Definitive Chemoradiotherapy to Salvage Treatment. International-journal

    Yusuke Taniyama, Keiichi Jingu, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Hirotaka Ishida, Naoto Ujiie, Michiaki Unno, Takashi Kamei

    Cancers　18　(11)　2026/05/22

    DOI： 10.3390/cancers18111681 　

    More details Close

    Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy in which radiotherapy plays a uniquely central role compared with other gastrointestinal cancers. Definitive chemoradiotherapy (dCRT) is widely used as a curative treatment; however, a substantial proportion of patients develop residual or recurrent disease, creating a complex clinical scenario that requires tailored salvage strategies. Salvage esophagectomy offers the potential for long-term survival but remains technically demanding and is associated with significant morbidity because of radiation-induced tissue damage. Less invasive local therapies, such as endoscopic submucosal dissection and photodynamic therapy, may provide effective treatment in selected patients, although their indications are limited by tumor characteristics and post-radiation fibrosis. In addition, immune checkpoint inhibitors have demonstrated promising efficacy in advanced ESCC and may represent a potential therapeutic option in the salvage setting. For patients who are not candidates for curative treatment, palliative esophageal stenting remains an important option for symptom relief, although prior radiotherapy may increase the risk of treatment-related complications. Given the diversity of available treatment modalities and their associated risks, a multidisciplinary and individualized treatment approach is essential. Further prospective studies are warranted to optimize treatment algorithms and improve outcomes in patients with ESCC after dCRT.

  22. Paratracheal Air Stripe Sign (PASS): A Useful Chest X-ray Finding for Diagnosis in Patients with Esophageal Achalasia. International-journal

    Naoto Ujiie, Yuto Muranami, Chiaki Sato, Yusuke Taniyama, Hiroshi Okamoto, Yohei Ozawa, Hirotaka Ishida, Ryohei Ando, Atsushi Kunimitsu, Michiaki Unno, Takashi Kamei

    Digestion　1-21　2026/02/05

    DOI： 10.1159/000550861 　

    More details Close

    INTRODUCTION: Esophageal achalasia is a rare motility disorder, and esophagogastroduodenoscopy (EGD) alone has limited diagnostic accuracy, often leading to delayed diagnosis. High-resolution manometry (HRM) remains the diagnostic gold standard, but its availability in primary care is limited. Therefore, more accessible diagnostic methods are needed. Given the widespread use of chest X-ray, we investigated whether it reveals distinctive features in achalasia patients. METHODS: In this retrospective cohort study, 215 patients with esophageal achalasia treated between 2015 and 2024 were analyzed. Diagnostic yields of EGD, esophagography, and computed tomography (CT) were evaluated among patients who underwent these examinations in primary care facilities. Chest X-rays were systematically reviewed for paratracheal radiolucency, and a novel radiographic sign-the Paratracheal Air Stripe Sign (PASS)-was defined as a paratracheal radiolucent area with a minimum width of ≥5 mm and length of ≥20 mm. To assess specificity, an additional analysis was performed in 210 patients with esophageal cancer as a non-achalasia control cohort. RESULTS: Diagnostic yields in primary care were 41.4% for EGD, 88.4% for esophagography, and 34.8% for CT. PASS was present in 67.0% of achalasia cases and more frequent in patients with type I achalasia, sigmoid-type morphology, and advanced esophageal dilation. Among patients undiagnosed by EGD, 63.9% exhibited PASS. In the non-achalasia control cohort, PASS was observed in 18.0% of cases, predominantly in patients with structural esophageal changes such as tortuosity or dilatation. CONCLUSION: PASS represents a novel and clinically useful chest X-ray feature associated with esophageal achalasia. Its relatively high prevalence, even among cases missed by EGD, and low occurrence in non-achalasia patients suggest that routine assessment of PASS in chest X-rays may aid early detection and timely referral for definitive diagnosis, particularly in primary care settings.

  23. Correlation of growth differentiation factor 15 level in esophageal cancer with cachectic indicators and postoperative infectious complication.

    Yohei Ozawa, Hiroshi Okamoto, Yusuke Taniyama, Chiaki Sato, Hirotaka Ishida, Takeya Sato, Shinobu Ohnuma, Michiaki Unno, Takaaki Abe, Takashi Kamei

    Esophagus : official journal of the Japan Esophageal Society　2025/09/29

    DOI： 10.1007/s10388-025-01157-0 　

    More details Close

    BACKGROUND: Patients with esophageal cancer (EC) usually have multiple comorbidities, particularly, high cachexia incidence, which may lead to increased postoperative complications. A novel inflammatory marker, growth differentiation factor 15 (GDF15), was recently reported to be associated with cancer cachexia. This study evaluated the correlation between clinical data suggestive of cachexia in patients with EC and circulating GDF15 levels. METHODS: Eighty patients with EC were enrolled in this study. Plasma samples were collected before initiating any cancer treatment. GDF15 was quantified using ELISA. Clinical information, including age, comorbidities, biochemical data, Controlling Nutritional Status score, and Psoas muscle index (PMI), was collected from the clinical records. Clinical impact of GDF15 was then evaluated and compared with cachectic indicators or postoperative results. RESULTS: The median value of GDF15 was 1168 pg/mL (range 298-9100 pg/mL). GDF15 values statistically correlated with age, prevalence of diabetes, serum level of aspartate aminotransferase/γ-glutamyltransferase/creatinine/blood sugar/albumin, and PMI. Sixty-three patients finally underwent curative esophagectomy with right thoracic approach and gastric tube reconstruction. Patients with infectious complications had a statistically higher GDF15 than those without. The cut-off value was 930 pg/mL for detecting infectious complications, with an area under the receiver operating characteristic curve value of 0.685, and high GDF15 was detected as an independent risk factor for postoperative infectious complications. CONCLUSIONS: GDF15 is potentially suggestive of general condition deterioration from aging, organ dysfunction, and decreased muscle mass, which may lead to cachexia in patients with EC. Moreover, patients with higher GDF15 are at a risk of postoperative infectious complications.

  24. Additional treatment for esophageal cancer patients with incomplete resection due to the surrounding organ invasion: a nationwide survey of 45 Japanese centers.

    Akihiko Okamura, Masayuki Watanabe, Jun Okui, Satoru Matsuda, Yoichi Hamai, Naoki Takahashi, Shinsuke Sato, Tetsuya Abe, Hirotaka Ishida, Hironobu Goto, Takeo Bamba, Tomokazu Kakishita, Eisuke Booka, Hidehiko Kitagami, Shirou Kuwabara, Yasue Kimura, Keisuke Kosumi, Sohei Matsumoto, Masanobu Nakajima, Seiya Inoue, Hiroyuki Kitagawa, Susumu Shibasaki, Noriaki Sadanaga, Katsushi Takebayashi, Toshiaki Shichinohe, Hirofumi Kawakubo, Yoshihiro Kakeji, Koji Kono, Yuko Kitagawa, Hiroya Takeuchi

    Esophagus : official journal of the Japan Esophageal Society　2025/09/16

    DOI： 10.1007/s10388-025-01155-2 　

    More details Close

    BACKGROUND: We occasionally experience incomplete resection of esophageal cancer due to the surrounding organ invasion. The efficacy of additional treatment in these cases is unknown. METHODS: We studied 445 patients with esophageal squamous cell carcinoma who were unable to undergo curative esophagectomy due to cancer invasion to the surrounding organs at 45 esophageal centers in Japan. Survival outcomes were compared based on the additional treatment modalities. RESULTS: Postoperatively, 175 (40.0%) received no additional treatment, while 59 (13.5%), 153 (35.0%), and 50 (11.4%) received additional chemotherapy, chemoradiotherapy, or radiotherapy, respectively. The three-year disease progression and overall survival rates were 90.6% (95% confidence interval 87.2-93.1%) and 15.4% (95% confidence interval 12.2-19.3%), respectively. Multivariable analysis revealed that chemotherapy, chemoradiotherapy, and radiotherapy were all independently associated with reduced disease progression (hazard ratios [95% confidence intervals]: 0.57 [0.40-0.81], 0.52 [0.39-0.69], and 0.48 [0.33-0.72], respectively). Meanwhile, additional treatment with chemotherapeutic agents (chemotherapy and chemoradiotherapy) was independently associated with better overall survival (hazard ratios [95% confidence intervals]: 0.51 [0.35-0.73] and 0.59 [0.44-0.79], respectively); however, radiotherapy alone had a limited impact (hazard ratio [95% confidence interval]: 0.74 [0.50-1.10]). CONCLUSIONS: Any additional treatment could suppress disease progression after incomplete resection, but radiotherapy alone has a limited effect. Additional systemic chemotherapeutics may increase patient survival.

  25. Expression of cluster of differentiation 47 (CD47) and signal regulatory protein alpha (SIRPα) as prognostic biomarkers and potentially therapeutic targets in esophageal squamous cell carcinoma.

    Junpeng Li, Yohei Ozawa, Takeru Mozumi, Kaiyuan Jiang, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Hirotaka Ishida, Naoto Ujiie, Shinobu Ohnuma, Michiaki Unno, Takashi Kamei

    Esophagus : official journal of the Japan Esophageal Society　2025/09/10

    DOI： 10.1007/s10388-025-01152-5 　

    More details Close

    BACKGROUND: The cluster of differentiation 47 (CD47)-signal regulatory protein alpha (SIRPα) axis is a key regulator of innate immune surveillance, facilitating the neoplastic evasion of macrophage-mediated phagocytosis. Although this pathway has been implicated in tumor immune escape in multiple malignancies, its clinical and prognostic significance in esophageal squamous cell carcinoma (ESCC) remain to be fully elucidated. METHODS: We retrospectively analyzed 100 patients who underwent esophagectomy for resectable ESCC. Immunohistochemical testing determined SIRPα expression in peritumoral immune infiltrates and CD47 expression in tumor and immune cells, while tumor proportion score (TPS) and combined positive score (CPS) were used to evaluate CD47 staining. Survival outcomes and correlations with clinicopathological factors were also analyzed. RESULTS: Increased expression of SIRPα, CD47 CPS, and CD47 TPS was detected in 47, 50, and 47% of patients, respectively. Elevated SIRPα expression was significantly associated with decreased overall survival. Also increased CD47 CPS and TPS was significantly associated with decreased overall survival and relapse-free survival. CD47 CPS was identified as an independent prognostic indicator for overall survival in multivariate Cox regression analysis (hazard ratio [HR] = 3.89; 95% confidence interval [CI] = 1.57-9.61; P = 0.003). Patients with concurrent high expression of both SIRPα and CD47 CPS demonstrated the poorest survival outcomes. CONCLUSION: Overexpression of SIRPα and CD47, especially in tandem, is associated with poor clinical outcomes in ESCC, suggesting that the CD47-SIRPα axis may serve as a useful prognostic biomarker and a potential therapeutic target for newly immune checkpoint blockade in ESCC.

  26. A Novel Approach for Cisplatin-Resistant Esophageal Squamous Cell Carcinoma via Amino Acid Transporter LAT1 Inhibition. International-journal

    Takeru Mozumi, Narumi Harada-Shoji, Yohei Ozawa, Yuto Yamazaki, Ryoyu Niikuni, Kentaro Imai, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Hirotaka Ishida, Atsushi Kunimitsu, Iku Sasaki-Higashimoto, Chisa Kobayashi, Shozo Furumoto, Takaaki Abe, Takashi Suzuki, Takashi Kamei

    Cancer medicine　14　(17)　e71234　2025/09

    DOI： 10.1002/cam4.71234 　

    More details Close

    BACKGROUND: Esophageal squamous cell carcinoma (ESCC) represents an aggressive cancer type associated with poor prognosis, often treated with neoadjuvant chemotherapy (NAC) using cisplatin-based regimens. However, cisplatin resistance limits therapeutic efficacy, necessitating a deeper understanding of resistance mechanisms. L-type amino acid transporter 1 (LAT1) plays a crucial role in amino acid uptake and is linked to cancer cell survival through activation of the mammalian target of rapamycin (mTOR) pathway. The involvement of LAT1 in cisplatin resistance in ESCC remains unclear. METHODS: LAT1 expression in ESCC patient samples post-NAC was evaluated by immunohistochemistry, and its association with clinicopathological factors and survival outcomes was analyzed. ESCC cell lines with varying cisplatin sensitivities were assessed for LAT1 expression using western blotting. Amino acid metabolism was examined via radiotracer uptake of 18F-FET and 18F-FDG. RNA sequencing was conducted to identify differentially expressed genes associated with mTOR signaling and autophagy. Finally, the effect of the LAT1 inhibitor JPH203 on cell proliferation was tested. RESULTS: High LAT1 expression was significantly associated with larger tumor size, lymph node metastasis, advanced pathological stage, and poor NAC response. Patients with high LAT1 expression exhibited shorter disease-free survival and overall survival. Cisplatin-resistant ESCC cells (KYSE520) showed elevated LAT1 expression, which further increased following cisplatin treatment. Radiotracer assays revealed that 18F-FET uptake was significantly higher in KYSE520 after cisplatin treatment compared to the sensitive cell line TE5. RNA sequencing identified regulation of mTOR pathway components and autophagy-related genes in cisplatin-resistant cells. Treatment with JPH203 significantly suppressed cell proliferation, particularly in KYSE520 cells, indicating LAT1's role in sustaining tumor cell survival under chemotherapy stress. CONCLUSION: LAT1 contributes to cisplatin resistance in ESCC by sustaining amino acid metabolism and promoting mTOR-dependent autophagy. Targeting LAT1 with JPH203 enhances cisplatin sensitivity, suggesting that LAT1 inhibition could be a promising therapeutic strategy for overcoming chemoresistance in ESCC.

  27. Supersulfide metabolome of exhaled breath condensate applied as diagnostic biomarkers for esophageal cancer. International-journal

    Seji Asamitsu, Yohei Ozawa, Hiroshi Okamoto, Seiryo Ogata, Tetsuro Matsunaga, Jun Yoshitake, Kazuki Fusegawa, Yusuke Taniyama, Chiaki Sato, Hirotaka Ishida, Takaaki Abe, Hozumi Motohashi, Takaaki Akaike, Takashi Kamei

    Cancer science　2025/02/02

    DOI： 10.1111/cas.16430 　

    More details Close

    Early detection of esophageal cancer is essential for esophagogastroduodenoscopy and histopathological diagnosis. However, endoscopic examinations are sometimes invasive, which limits their clinical application and compliance, and traditional blood tumor markers are unsuitable for cancer screening. The current study aimed to evaluate the usefulness of sulfur metabolites as new biomarkers for esophageal cancer using blood samples and exhaled breath condensate (EBC), which can be readily obtained and is non-invasive. We collected EBC and plasma samples from 50 patients with esophageal cancer and 30 healthy controls. Sulfur metabolome analysis using tandem mass spectrometry was performed to compare the metabolic profile between the two groups. Supersulfide metabolic profiles were different between the two cohorts. Supersulfide metabolome analysis showed that cysteine hydropersulfide (CysSSH) and homocysteine hydropersulfide (HomoCysSSH) were increased in the plasma of patients with esophageal cancer. Elevated levels of HomoCysSSH could distinguish patients with esophageal cancer from healthy subjects (area under the curve [AUC]: 0.93, sensitivity: 89%, specificity: 96%). Interestingly, we also detected an elevation of supersulfides in the EBC analysis. CysSSH levels significantly increased in the EBC recovered from patients with esophageal cancer (AUC: 0.71, sensitivity: 60%, specificity: 96%). In addition, the observed level was correlated with that of HomoCysSSH in the plasma (r = 0.27). Supersulfides, such as CysSSH and HomoCysSSH, are potential biomarkers for detecting esophageal cancer. CysSSH from EBC may serve as a valuable non-invasive biomarker with similar detection ability but with superior precision and convenience compared with the currently available blood biomarkers.

  28. Histopathological study of the localization/distribution of Fusobacterium nucleatum in esophageal cancer Peer-reviewed

    Iku Sasaki‐Higashimoto, Fumiyoshi Fujishima, Hirotaka Ishida, Yusuke Taniyama, Yohei Ozawa, Tomohiro Nakamura, Naoki Nakaya, Chiaki Sato, Hiroshi Okamoto, Junichi Tsunokake, Atsushi Kunimitsu, Takeru Mozumi, Takashi Kamei, Takashi Suzuki

    Pathology International　2025/02

    DOI： 10.1111/pin.13505 　

  29. Multimodal deep-learning model using pre-treatment endoscopic images and clinical information to predict efficacy of neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Peer-reviewed

    Takuma Miura, Takumi Yashima, Eichi Takaya, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Hirotaka Ishida, Michiaki Unno, Takuya Ueda, Takashi Kamei

    Esophagus : official journal of the Japan Esophageal Society　2025/01/10

    DOI： 10.1007/s10388-025-01106-x 　

    More details Close

    BACKGROUND: Neoadjuvant chemotherapy is standard for advanced esophageal squamous cell carcinoma, though often ineffective. Therefore, predicting the response to chemotherapy before treatment is desirable. However, there is currently no established method for predicting response to neoadjuvant chemotherapy. This study aims to build a deep-learning model to predict the response of esophageal squamous cell carcinoma to preoperative chemotherapy by utilizing multimodal data integrating esophageal endoscopic images and clinical information. METHODS: 170 patients with locally advanced esophageal squamous cell carcinoma were retrospectively studied, and endoscopic images and clinical information before neoadjuvant chemotherapy were collected. Endoscopic images alone and endoscopic images plus clinical information were each analyzed with a deep-learning model based on ResNet50. The clinical information alone was analyzed using logistic regression machine learning models, and the area under a receiver operating characteristic curve was calculated to compare the accuracy of each model. Gradient-weighted Class Activation Mapping was used on the endoscopic images to analyze the trend of the regions of interest in this model. RESULTS: The area under the curve by clinical information alone, endoscopy alone, and both combined were 0.64, 0.55, and 0.77, respectively. The endoscopic image plus clinical information group was statistically more significant than the other models. This model focused more on the tumor when trained with clinical information. CONCLUSIONS: The deep-learning model developed suggests that gastrointestinal endoscopic imaging, in combination with other clinical information, has the potential to predict the efficacy of neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma before treatment.

  30. Prevention and Management of Recurrent Laryngeal Nerve Palsy in Minimally Invasive Esophagectomy: Current Status and Future Perspectives. International-journal Peer-reviewed

    Yusuke Taniyama, Hiroshi Okamoto, Chiaki Sato, Yohei Ozawa, Hirotaka Ishida, Michiaki Unno, Takashi Kamei

    Journal of clinical medicine　13　(24)　2024/12/13

    DOI： 10.3390/jcm13247611 　

    More details Close

    Recurrent laryngeal nerve palsy remains a significant complication following minimally invasive esophagectomy for esophageal cancer. Despite advancements in surgical techniques and lymphadenectomy precision, the incidence of recurrent laryngeal nerve palsy has not been improved. Recurrent laryngeal nerve palsy predominantly affects the left side and may lead to unilateral or bilateral vocal cord paralysis, resulting in hoarseness, dysphagia, and an increased risk of aspiration pneumonia. While most cases of recurrent laryngeal nerve palsy are temporary and resolve within 6 to 12 months, some patients may experience permanent nerve dysfunction, severely impacting their quality of life. Prevention strategies, such as nerve integrity monitoring, robotic-assisted minimally invasive esophagectomy, and advanced dissection techniques, aim to minimize nerve injury, though their effectiveness varies. The management of recurrent laryngeal nerve palsy includes voice and swallowing rehabilitation, reinnervation techniques, and, in severe cases, surgical interventions such as thyroplasty and intracordal injection. As recurrent laryngeal nerve palsy can lead to significant postoperative respiratory complications, a multidisciplinary approach involving surgical precision, early detection, and comprehensive rehabilitation is crucial to improving patient outcomes and minimizing long-term morbidity in minimally invasive esophagectomy. This review article aims to inform esophageal surgeons and other clinicians about strategies for the prevention and management of recurrent laryngeal nerve palsy in esophagectomy.

  31. Risk Factors and Treatment of Chylothorax After Minimally Invasive Esophagectomy for Esophageal Cancer. International-journal Peer-reviewed

    Yuma Tsuchitani, Yohei Ozawa, Yusuke Taniyama, Hiroshi Okamoto, Chiaki Sato, Hirotaka Ishida, Takashi Kamei

    Cureus　16　(7)　e65606　2024/07

    DOI： 10.7759/cureus.65606 　

    More details Close

    Background Postoperative chylothorax is a rare but life-threatening complication of esophagectomy. However, due to its rarity, researching the risk factors and selecting appropriate treatment options has been limited. Methods This study included 727 patients with esophageal cancer who underwent minimally invasive esophagectomy at our hospital. To detect the risk factors for chylothorax, we divided the patients into two groups, with and without postoperative chylothorax. We then compared patient characteristics, tumor-specific variables, and operative details. Subsequently, we analyzed the peri-treatment characteristics and outcomes for the three distinct treatment options we had chosen: surgery, conversion (the group that finally underwent surgery after unsuccessful conservative treatment), and conservative. Results Of the 727 patients, 18 (2.5%) developed a chylothorax. The mean BMI was lower (20.3 vs. 21.9, p=0.057), and more cases of thoracic duct resection were found in the chylothorax group (33.3% vs. 6.2%, p=0.001), with statistical significance. Multivariate analysis identified thoracic duct resection as a risk factor (adjusted odds ratio, 6.83). The drainage volume two days after chylothorax was higher in the surgery group, although the difference was not statistically significant (surgery group, 1,405 ml vs. conversion group, 260 ml vs. conservative group, 310 ml; p=0.073). The surgery group had the shortest median postoperative hospital days among these groups (21.5 as compared to 102 and 25.0 days in the conversion and conservative groups, respectively; p<0.001). None of the patients died during their hospital stays. Conclusion Thoracic duct resection during the initial minimally invasive esophagectomy was an independent risk factor for chylothorax. If drainage volume does not decrease on the second day, early surgery may lead to earlier discharge.

  32. Supersulfide metabolome of exhaled breath condensate for diagnostic biomarkers of esophageal cancer

    Hirotaka Ishida

    JOURNAL OF CLINICAL ONCOLOGY　2024

  33. Correlation of plasma GDF15 with aging, organ disfunction, sarcopenia, and postoperative infectious complication in patients with esophageal cancer

    Hirotaka Ishida

    JOURNAL OF CLINICAL ONCOLOGY　2024

  34. Distinguishing Killian-Jamieson diverticulum from Zenker's diverticulum. International-journal Peer-reviewed

    Yuki Watanabe, Yusuke Taniyama, Ken Koseki, Hirotaka Ishida, Yohei Ozawa, Hiroshi Okamoto, Chiaki Sato, Michiaki Unno, Takashi Kamei

    Surgical case reports　9　(1)　21-21　2023/02/10

    DOI： 10.1186/s40792-023-01599-7 　

    More details Close

    BACKGROUND: Killian-Jamieson diverticulum, which is a relatively rare pharyngoesophageal diverticulum, is difficult to distinguish from Zenker's diverticulum. Because major points of the relevant surgical procedures for these two entities differ, it is important to make an accurate diagnosis. We herein report a case of Killian-Jamieson diverticulum initially diagnosed as Zenker's diverticulum. CASE PRESENTATION: A 56-year-old man complaining of discomfort during swallowing was diagnosed with pharyngoesophageal diverticulum. He was initially diagnosed with Zenker's diverticulum before surgery, but the diverticulum actually arose from the left side of the esophageal wall, at the level of the cricoid cartilage and below the cricopharyngeal muscle. We therefore ultimately diagnosed this case as Killian-Jamieson diverticulum during surgery, and were able to preserve the muscle above the diverticulum, which would normally have to be cut when treating a case of Zenker's diverticulum. CONCLUSION: To make an accurate diagnosis, clinical and surgical findings are important to consider, including the location of the diverticulum and the relationship between the diverticula and cricopharyngeal muscles or between the diverticula, thyroid cartilage and cricoid cartilage.

  35. Perioperative Administration of Cystine and Theanine Suppresses Inflammation and Facilitates Early Rehabilitation and Recovery after Esophagectomy: A Randomized, Double-Blind, Controlled Clinical Trial. International-journal Peer-reviewed

    Hiroshi Okamoto, Yusuke Taniyama, Tadashi Sakurai, Gaku Kodama, Chiaki Sato, Toshiaki Fukutomi, Yohei Ozawa, Hirotaka Ishida, Ken Koseki, Takuro Yamauchi, Toru Nakano, Michiaki Unno, Takashi Kamei

    Nutrients　14　(11)　2022/05/31

    DOI： 10.3390/nu14112319 　

    More details Close

    Oral administration of cystine and theanine (CT) increases glutathione levels to modulate the inflammatory response, which has yet to be sufficiently explored for patients' recovery and early rehabilitation. We planned a randomized, double-blind, placebo-controlled trial to determine whether perioperative oral administration of CT promotes recovery after esophagectomy. Patients were randomized into either CT or placebo groups, who received preoperative and postoperative treatments for 4 and 13 days, respectively. The main outcome measures were triaxial accelerometer readings, inflammation indicators, a 6 min walk test (6MWT), and a quality of life questionnaire (QoR-40). The study involved 32 patients. Although the CT group (n = 16) showed better patient activity across the investigated period, there was no significant difference between the two groups. However, white blood cell count on postoperative days (POD) 2 and 10, neutrophil count (POD 2, 7, and 10), and C-reactive protein level (POD 13) in the CT group were significantly lower than in the placebo group. Furthermore, 6MWT on POD 7 and QoR-40 on POD 13 were significantly higher in the CT group than those in the placebo group. This study suggests that perioperative administration of CT may contribute to early recovery and rehabilitation after esophagectomy via suppression of inflammatory response.

  36. Correlation between TXNRD1/HO-1 expression and response to neoadjuvant chemoradiation therapy in patients with esophageal squamous cell carcinoma. Peer-reviewed

    Ryujiro Akaishi, Fumiyoshi Fujishima, Hirotaka Ishida, Junichi Tsunokake, Takuro Yamauchi, Yusuke Gokon, Shunsuke Ueki, Toshiaki Fukutomi, Hiroshi Okamoto, Kai Takaya, Chiaki Sato, Yusuke Taniyama, Tomohiro Nakamura, Naoki Nakaya, Takashi Kamei, Hironobu Sasano

    Esophagus : official journal of the Japan Esophageal Society　19　(3)　436-443　2022/01/08

    DOI： 10.1007/s10388-021-00904-3 　

    More details Close

    BACKGROUND: Thioredoxin reductase 1 (TXNRD1) and heme oxygenase-1 (HO-1) are both involved in the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and play key roles in antioxidant responses. In patients with esophageal squamous cell carcinoma (ESCC), the correlation between the expression of these two proteins and the therapeutic response to neoadjuvant chemoradiation therapy (NACRT), as well as the difference in their expression after chemoradiotherapy, remains unknown. METHODS: Proteins involved in the Nrf2 pathway were immunolocalized in carcinoma cells in ESCC patients on NACRT with 5-fluorouracil and cisplatin, followed by esophagectomy. The 8-hydroxydeoxyguanosine (8-OHdG) levels were used to quantify reactive oxygen species. The changes in immunoreactivity before and after NACRT (Δ) were assessed. RESULTS: Tumor reduction following NACRT was significantly attenuated in pre-therapeutic biopsy specimens associated with high HO-1 status. TXNRD1Δ, HO-1Δ, and 8-OHdGΔ were significantly different in the ineffective and effective groups. The overall survival was significantly lower in high Nrf2 and TXNRD1 groups. In addition, high TXNRD1 expression was an independent prognostic factor in the multivariate analysis of overall survival. CONCLUSIONS: The study findings indicate that HO-1 status in pre-therapeutic biopsy specimens could predict response to NACRT, and TXNRD1 status could predict overall survival of ESCC patients.

  37. Minimally Invasive Surgery for Sternoclavicular Joint Infection with Osteomyelitis, Large Abscesses, and Mediastinitis. International-journal

    Hideki Ota, Hirotaka Ishida, Hidekazu Matsumoto, Tomoharu Ishiyama

    Case reports in surgery　2022　9461619-9461619　2022

    DOI： 10.1155/2022/9461619 　

    More details Close

    BACKGROUND: Sternoclavicular joint infections require en bloc resection for radical cure; however, this aggressive procedure may result in multiple adverse events. Therefore, performing minimally invasive surgery is desirable. In this report, we describe a case of sternoclavicular joint infection complicated by osteomyelitis, large abscesses, and mediastinitis that was successfully treated with incision and drainage. Case Presentation. A 42-year-old man with no medical history presented to our hospital with complaints of painful swelling in the left chest wall and acute dyspnea. Computed tomography revealed arthritis of the left sternoclavicular joint, osteomyelitis of the clavicle and sternum, anterior mediastinitis, and abscesses in the neck, chest wall, and retrosternal and extrapleural spaces. Gram staining of the aspirated pus revealed clusters of gram-positive cocci. A diagnosis of Staphylococcus aureus sternoclavicular joint infection with locoregional spread was made. Emergency surgery was performed following adequate resuscitation. A skin incision was made in the second intercostal space. The joint capsule was widely opened, necrotic tissue was curetted, and closed suction drains were placed in the abscess cavities and connected to a negative pressure system. The wound was then closed using primary sutures. The postoperative course was uneventful. Methicillin-sensitive Staphylococcus aureus was cultured from the pus. The patient was discharged on postoperative day 14. Osteomyelitis worsened within a few weeks after surgery but recovered with wound management and six weeks of antibiotic therapy. The patient has had no recurrence of infection for two years. CONCLUSIONS: Incision and drainage proved to be an effective minimally invasive surgical treatment for sternoclavicular joint infection with osteomyelitis, large abscesses, and mediastinitis caused by methicillin-sensitive Staphylococcus aureus.

  38. HO-1 in lymph node metastasis predicted overall survival in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation therapy. International-journal Peer-reviewed

    Ryujiro Akaishi, Fumiyoshi Fujishima, Hirotaka Ishida, Junichi Tsunokake, Takuro Yamauchi, Yusuke Gokon, Shunsuke Ueki, Toshiaki Fukutomi, Hiroshi Okamoto, Kai Takaya, Chiaki Sato, Yusuke Taniyama, Tomohiro Nakamura, Naoki Nakaya, Takashi Kamei, Hironobu Sasano

    Cancer reports (Hoboken, N.J.)　5　(3)　e1477　2021/07/15

    DOI： 10.1002/cnr2.1477 　

    More details Close

    BACKGROUND: Lymph node metastasis is one of the pivotal factors of the clinical outcomes of patients with esophageal cancer receiving neoadjuvant chemoradiation therapy (NACRT). Both the nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway and heme oxygenase-1 (HO-1) are frequently upregulated in various human malignancies and associated with resistance to chemoradiation therapy, subsequently resulting in adverse clinical outcomes. However, the Nrf2 and HO-1 status in lymph node metastasis and their differences between primary and metastatic lesions are unknown. AIMS: To examine the levels of Nrf2 signaling proteins and HO-1 in primary and metastatic lesions of patients with esophageal squamous cell carcinoma using immunohistochemistry. METHODS AND RESULTS: We immunolocalized Nrf2 signaling proteins in 69 patients with lymph node metastases, who received NACRT with 5-fluorouracil and cisplatin before esophagectomy. We also compared the findings between primary and metastatic lesions. Residual lymph node metastases were detected in 30 patients and among them, both primary and metastatic lesions were available for evaluation in 25 patients. Subsequently, we correlated the results with patients' survival. Nrf2, HO-1, and the Ki-67 labeling index were all significantly lower in the patients with lymph node metastases than in those with primary tumors. Carcinoma cells with high HO-1 levels were significantly associated with pathological resistance to NACRT. These results suggested that overall and disease-free survival of esophageal squamous cell carcinoma were significantly associated with both pN2 and high HO-1 levels, respectively. CONCLUSIONS: Protein expression in the Nrf2 pathway was significantly lower in patients with lymph node metastases than in those with primary lesions. HO-1 levels in lymph node metastases could be used to predict the eventual clinical outcome of patients with esophageal cancer receiving NACRT.

  39. An extremely rare case of desmoplastic fibroblastoma exhibiting rapid growth in the chest wall: a case report. International-journal Peer-reviewed

    Hideki Ota, Hirotaka Ishida, Hidekazu Matsumoto, Tomoharu Ishiyama

    Surgical case reports　7　(1)　86-86　2021/04/07

    DOI： 10.1186/s40792-021-01171-1 　

    More details Close

    BACKGROUND: Desmoplastic fibroblastoma is an uncommon, benign, fibrous tumor exhibiting infiltrative growth. Most of these tumors are small, slow-growing, and develop as subcutaneous lesions in the extremities. Cases of desmoplastic fibroblastoma in the chest wall are quite rare, and the preoperative diagnosis of such cases remains challenging as these tumors can mimic the characteristics of desmoid-type fibromatosis, which often occurs in the chest wall. We aimed to describe a rare case of desmoplastic fibroblastoma exhibiting rapid growth in the chest wall of a patient that was successfully treated with marginal excision only by diagnostic imaging before surgery. CASE PRESENTATION: A 79-year-old man was admitted to our hospital after experiencing right shoulder pain lasting for a few months. A 4 × 4 × 2 cm mass was incidentally detected at the right second rib two years prior. Chest computed tomography revealed a well-defined homogeneous mass with a muscle-like density along the right lateral chest wall, the size of which had increased to 12 × 10 × 4.5 cm in two years. Dynamic contrast-enhanced computed tomography revealed abundant vascularity at the periphery of the tumor. Magnetic resonance imaging revealed iso-intensity to muscle on T1-weighted images, slightly high intensity on T2-weighted images, and rim-like contrast enhancement at the periphery of the tumor, with uniform thickness on gadolinium-enhanced T1-weighted images with fat suppression. Rim-like contrast enhancement is an imaging feature that can distinguish cases of desmoplastic fibroblastoma from desmoid-type fibromatosis. We diagnosed the tumor as desmoplastic fibroblastoma by diagnostic imaging without tissue biopsy. Marginal excision with videoscopic assistance was performed through a small incision. The pathological diagnosis was desmoplastic fibroblastoma. The patient's postoperative course was uneventful, and his shoulder pain was relieved after the surgery. CONCLUSIONS: Desmoplastic fibroblastoma in the chest wall is extremely rare, but should be considered in the differential diagnosis when desmoid-type fibromatosis is clinically suspected. Gadolinium-enhanced magnetic resonance imaging is helpful in confirming the differential diagnosis.

  40. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression. International-journal Peer-reviewed

    Yusuke Gokon, Fumiyoshi Fujishima, Yusuke Taniyama, Hirotaka Ishida, Taku Yamagata, Takashi Sawai, Miwa Uzuki, Hirofumi Ichikawa, Yuko Itakura, Kazutomi Takahashi, Nobuhisa Yajima, Motohisa Hagiwara, Akiko Nishida, Yohei Ozawa, Tsutomu Sakuma, Rikiya Kanba, Kazuhiro Sakamoto, Masashi Zuguchi, Masahiro Saito, Takashi Kamei, Hironobu Sasano

    Virchows Archiv : an international journal of pathology　477　(6)　825-834　2020/12

    DOI： 10.1007/s00428-020-02854-0 　

    More details Close

    The immune microenvironment plays a pivotal role in cancer development and progression. Therefore, we studied the status of immune cells in esophageal adenocarcinoma (EAC) and adjacent Barrett's esophagus (BE) and their association with the clinical course of patients. We included 87 patients with EAC who underwent surgical resection or endoscopic submucosal dissection. CD3, CD8, Foxp3, p53, and Ki-67 were immunolocalized in EAC and adjacent BE (N = 87) and BE without EAC (N = 13). BE adjacent to EAC exhibited higher CD3+ lamina propria lymphocyte (LPL) numbers than BE without EAC. Abundant Foxp3+ LPLs in BE were associated with dysplasia and increased Ki-67 labeling index (LI) in BE glandular cells and tended to link to aberrant p53 expression. Abundant CD8+ LPLs in adjacent BE were associated with worse prognosis of EAC patients (P = 0.019). Results of our present study firstly revealed the potential influence of the tissue immune microenvironment of BE adjacent to EAC on cancer development and eventual clinical outcome of EAC patients. T cell infiltration could play pivotal roles in facilitating the dysplasia-adenocarcinoma sequence in BE. The number of Foxp3+ T cells is increased at the early stage of carcinogenesis and could help identify patients harboring dysplastic and highly proliferating cells. CD8+ T cells could reflect unfavorable inflammatory response in adjacent tissue microenvironment and help predict worse prognosis of EAC patients.

  41. Glucocorticoid receptor and serum- and glucocorticoid-induced kinase-1 in esophageal adenocarcinoma and adjacent Barrett's esophagus. International-journal Peer-reviewed

    Yusuke Gokon, Fumiyoshi Fujishima, Yusuke Taniyama, Hirotaka Ishida, Taku Yamagata, Takashi Sawai, Miwa Uzuki, Hirofumi Ichikawa, Yuko Itakura, Kazutomi Takahashi, Nobuhisa Yajima, Motohisa Hagiwara, Akiko Nishida, Yohei Ozawa, Tsutomu Sakuma, Kazuhiro Sakamoto, Masashi Zuguchi, Masahiro Saito, Takashi Kamei, Hironobu Sasano

    Pathology international　70　(6)　355-363　2020/06

    DOI： 10.1111/pin.12922 　

    More details Close

    Barrett's esophagus (BE) is a consequence of gastroesophageal reflux disease and is predisposed to esophageal adenocarcinoma (EAC). EAC is an exemplar model of inflammation-associated cancer. Glucocorticoids suppress inflammation through glucocorticoid receptor (GR) and serum- and glucocorticoid-induced kinase-1 (Sgk1) expressions. Therefore, we immunolocalized GR and Sgk1 in EAC and the adjacent BE tissues and studied their association with clinical disease course in 87 patients with EAC who underwent surgical resection (N = 58) or endoscopic submucosal dissection (N = 29). Low GR and Sgk1 expressions in adjacent BE tissues were associated with adverse clinical outcomes (P = 0.0008 and 0.034, respectively). Patients with low Sgk1 expression in EAC cells exhibited worse overall survival (P = 0.0018). In multivariate Cox regression analysis, low GR expression in the adjacent nonmalignant BE tissues was significantly associated with worse overall survival (P = 0.023). The present study indicated that evaluation of GR and Sgk1 expressions in both the EAC cells and adjacent nonmalignant BE tissues could help to predict clinical outcomes following endoscopic and surgical treatments. In particular, the GR status in BE tissues adjacent to EAC was an independent prognostic factor.

  42. GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy. International-journal Peer-reviewed

    Shunsuke Ueki, Fumiyoshi Fujishima, Takuro Kumagai, Hirotaka Ishida, Hiroshi Okamoto, Kai Takaya, Chiaki Sato, Yusuke Taniyma, Takashi Kamei, Hironobu Sasano

    BMC cancer　20　(1)　161-161　2020/02/27

    DOI： 10.1186/s12885-020-6652-7 　

    More details Close

    BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a highly malignant neoplasm. The glucocorticoid (GC)-glucocorticoid receptor (GR) pathway plays pivotal roles in cellular response to various stresses of tumor cells, including chemotherapy. However, the status of the GC-GR pathway in ESCC, including its correlation with chemotherapeutic responses, is largely unknown. METHODS: GR, serum-and glucocorticoid-regulated kinase 1 (Sgk1), and N-myc down regulation gene 1 (NDRG1) were immunolocalized in 98 patients with ESCC who had undergone esophagectomy following neoadjuvant chemotherapy (NAC) with 2 courses of 5-fluorouracil + cisplatin. We also examined biopsy specimens before NAC in 42 cases and compared the results between those before and after NAC. RESULTS: Overall survival (OS) of the patients treated with surgery following NAC was significantly shorter in the group with high GR than that with low GR status (P = 0.0473). Both OS and disease-free survival (DFS) were significantly shorter in both Sgk1- and NDRG1-high groups than in the low groups (OS: Sgk1, P = 0.0055; NDRG1, P = 0.0021; DFS: Sgk1, P = 0.0240; NDRG1, P = 0.0086). Biopsy specimens before NAC showed significantly shorter DFS in the high Sgk1 group (P = 0.0095), while both OS and DFS were shorter in the high NDRG1 group (OS, P = 0.0233; DFS, P = 0.0006) than in the respective low groups. In the high NDRG1 group of biopsy specimens before NAC, the tumor reduction rate by NAC was significantly attenuated (P = 0.021). CONCLUSIONS: High GR, Sgk1, and NDRG1 statuses in ESCC after NAC was significantly associated with an overall worse prognosis, with no significant changes in their expression levels before and after NAC. Therefore, increased activity of the GC-GR pathway with enhanced induction of Sgk1 and NDRG1 in carcinoma cells play pivotal roles in tumor progression and development of chemo-resistance in patients with ESCC undergoing NAC.

  43. 内視鏡的に根治し得た落下胃石嵌頓によるイレウスの1例 Peer-reviewed

    早坂 研, 石田 裕嵩, 斉藤 真由子

    Gastroenterological Endoscopy　61　(9)　1656-1662　2019/09

    Publisher: (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  44. Myosin 5a regulates tumor migration and epithelial-mesenchymal transition in esophageal squamous cell carcinoma: utility as a prognostic factor. International-journal Peer-reviewed

    Naomi Sato, Fumiyoshi Fujishima, Yasuhiro Nakamura, Yayoi Aoyama, Yoshiaki Onodera, Yohei Ozawa, Ken Ito, Hirotaka Ishida, Takashi Kamei, Mika Watanabe, Hironobu Sasano

    Human pathology　80　113-122　2018/10

    DOI： 10.1016/j.humpath.2018.06.002 　

    More details Close

    Esophageal squamous cell carcinoma (ESCC) is highly malignant. Recently, the expression of myosin 5a, a member of the myosin superfamily, was reported to be associated with increased invasiveness and metastasis in many tumor types. Moreover, myosin 5a is upregulated by Snail and activated by Akt2, both of which are epithelial-mesenchymal transition (EMT) markers. In this study, we confirmed the expression of myosin 5a in ESCC surgical specimens and cell lines, revealing its correlation with tumor invasion, migration, patient prognosis, and expression of EMT-related proteins. The expression of myosin 5a, vimentin, and E-cadherin was immunohistochemically evaluated in 118 patients with ESCC who underwent esophagectomy without chemotherapy or irradiation therapy prior to surgery. We also investigated ESCC cell migration under myosin 5a silencing by siRNA induction. The high expression of myosin 5a was correlated with tumor depth, lymph node metastasis, pathological stage, high vimentin expression, and low E-cadherin expression. Patients with high expression of myosin 5a, including those with pT1 cancer, exhibited significantly worse survival. Moreover, the expression level of vimentin mRNA and the number of migrated ESCC cells decreased significantly following myosin 5a silencing. Our findings demonstrate that high expression of myosin 5a may be an independent prognostic factor in patients with ESCC, even in early invasive carcinoma, and indicate myosin 5a has a role in both cell migration and EMT.

  45. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. Peer-reviewed

    Hiroshi Okamoto, Yusuke Taniyama, Tadashi Sakurai, Takahiro Heishi, Jin Teshima, Chiaki Sato, Shota Maruyama, Ken Ito, Yu Onodera, Takuro Konno-Kumagai, Hirotaka Ishida, Takashi Kamei

    Esophagus : official journal of the Japan Esophageal Society　15　(4)　281-285　2018/10

    DOI： 10.1007/s10388-018-0627-7 　

    More details Close

    BACKGROUND: Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. Our department recently introduced dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for treating advanced cervical ESCC. This study aims to assess the safety and outcomes of DCF-R in patients with advanced cervical ESCC. METHODS: We retrospectively assessed 11 patients with advanced cervical ESCC (clinical stage: II-IV, including T4b and/or M1 lymph node) who received DCF-R as the first-line treatment between December 2010 and February 2015. RESULTS: Our patient cohort comprised 8 males and 3 females (median age 68 years; range 54-76 years). The pretreatment clinical stage included stage II (1), stage III (7), and stage IV (3) cases [including 3 patients with T4b (2 trachea and 1 thyroid) and 3 patients with M1 lymph node]. We attained complete response (CR) in 10 patients and stable disease in 1 patient. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Furthermore, grade 3 or more adverse events included leucopenia (91%), neutropenia (91%), febrile neutropenia (45%), and pharyngeal pain (55%). While the 2-year overall survival rate was 72%, the 2-year recurrent-free survival rate was 64%, respectively. CONCLUSIONS: DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation.

  46. Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy. Peer-reviewed

    Fujishima F, Taniyama Y, Nakamura Y, Okamoto H, Ozawa Y, Ito K, Ishida H, Konno-Kumagai T, Kasajima A, Taniuchi S, Watanabe M, Kamei T, Sasano H

    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus　31　(7)　2018/07

    DOI： 10.1093/dote/dox141 　

    ISSN： 1120-8694

  47. Treatment of spontaneous esophageal rupture (Boerhaave syndrome) using thoracoscopic surgery and sivelestat sodium hydrate. International-journal Peer-reviewed

    Hiroshi Okamoto, Ko Onodera, Rikiya Kamba, Yusuke Taniyama, Tadashi Sakurai, Takahiro Heishi, Jin Teshima, Makoto Hikage, Chiaki Sato, Shota Maruyama, Yu Onodera, Hirotaka Ishida, Takashi Kamei

    Journal of thoracic disease　10　(4)　2206-2212　2018/04

    DOI： 10.21037/jtd.2018.03.136 　

    More details Close

    Background: The mortality rate of spontaneous esophageal rupture remains 20% to 40% due to severe respiratory failure. We have performed thoracoscopic surgery for esophageal disease at our department since 1994. Sivelestat sodium hydrate reportedly improves the pulmonary outcome in the patients with acute lung injury (ALI). Methods: We retrospectively evaluated the usefulness of thoracoscopic surgery and perioperative administration of sivelestat sodium hydrate for spontaneous esophageal rupture in 12 patients who underwent thoracoscopy at our department between 2002 and 2014. Results: The patient cohort included 11 males and one female (median age, 61 years). The lower left esophageal wall was perforated in all patients. Surgical procedures consisted of thoracoscopic suture and thoracic drainage in six patients, transhiatal suture and thoracoscopic thoracic drainage in five, and thoracoscopic esophagectomy and thoracic drainage in one. The median time from onset to surgery was 8 hours with a surgical duration of 210 minutes, blood loss 260 mL, postoperative ventilator management 1 day, intensive care unit (ICU) stay 5 days, and interval to restoration of oral ingestion 13 days. Postoperative complications included respiratory failure in four patients, pyothorax in three, and leakage in one. There was no instance of perioperative mortality. Regarding perioperative administration of sivelestat sodium hydrate, the postoperative arterial oxygen partial pressure-to-fractional inspired oxygen ratio (P/F) and C-reactive protein (CRP) levels in the administration group were significantly better than those in the non-administration group on postoperative days 4 (P=0.035) and 5 (P=0.037), respectively. In contrast, there was no significant difference between the groups in median time of ventilator management, ICU stay, oral ingestion following surgery, or hospital stay. Conclusions: Thoracoscopic surgery obtained acceptable results in all patients, including two with a significant time elapse from onset to treatment. Furthermore, sivelestat sodium hydrate was suggested to help improve postoperative respiration and inflammatory response.

  48. Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors. International-journal Peer-reviewed

    Atsuko Kasajima, Yuichi Ishikawa, Ayaka Iwata, Katja Steiger, Naomi Oka, Hirotaka Ishida, Akira Sakurada, Hiroyoshi Suzuki, Toru Kameya, Björn Konukiewitz, Günter Klöppel, Yoshinori Okada, Hironobu Sasano, Wilko Weichert

    Endocrine-related cancer　25　(3)　339-350　2018/03

    DOI： 10.1530/ERC-17-0427 　

    More details Close

    In the light of novel cancer immune therapies, the status of antitumor inflammatory response and its regulation has gained much attention in patients with lung cancer. Ample datasets exist for non-small-cell lung cancer, but those for pulmonary neuroendocrine tumors are scarce and controversial. Here, tumor-associated inflammation, CD8+ cell infiltration and PD-L1 status were evaluated in a cohort of 57 resected carcinoids and 185 resected neuroendocrine carcinomas of the lung (58 large cell carcinomas and 127 small cell carcinomas). Data were correlated with clinicopathological factors and survival. Moderate or high tumor-associated inflammation was detected in 4 carcinoids (7%) and in 37 neuroendocrine carcinomas (20%). PD-L1 immunoreactivity was seen in immune cells of 73 (39%) neuroendocrine carcinomas, while tumor cells were labeled in 21 (11%) cases. Inflammatory cells and tumor cells in carcinoids lacked any PD-L1 expression. In neuroendocrine carcinomas, PD-L1 positivity in immune cells, but not in tumor cells, was associated with intratumoral CD8+ cell infiltration (P < 0.001), as well as with the severity of tumor-associated inflammation (P < 0.001). In neuroendocrine carcinomas, tumor-associated inflammation and PD-L1 positivity in immune cells correlated with prolonged survival and the latter factor was also an independent prognosticator (P < 0.01, hazard ratio 0.4 for overall survival, P < 0.001 hazard ratio 0.4 for disease-free survival). Taken together, in neuroendocrine tumors, antitumor inflammatory response and PD-L1 expression are largely restricted to neuroendocrine carcinomas, and in this tumor entity, PD-L1 expression in inflammatory cells is positively correlated to patient survival.

  49. Different strategy of salvage esophagectomy between residual and recurrent esophageal cancer after definitive chemoradiotherapy. International-journal Peer-reviewed

    Yusuke Taniyama, Tadashi Sakurai, Takahiro Heishi, Hiroshi Okamoto, Chiaki Sato, Shota Maruyama, Yu Onodera, Hirotaka Ishida, Michiaki Unno, Takashi Kamei

    Journal of thoracic disease　10　(3)　1554-1562　2018/03

    DOI： 10.21037/jtd.2018.03.04 　

    More details Close

    Background: Clinical outcomes appear to differ between patients with residual or recurrent esophageal cancer after definitive chemoradiotherapy. We aimed to identify the patients most likely to benefit from this high-risk surgery, divided by the patients whose cancer was residual and recurrent groups, respectively. Methods: We retrospectively examined 100 cases of patients who failed to respond to definitive chemoradiotherapy for thoracic esophageal squamous cell carcinoma and subsequently underwent salvage transthoracic esophagectomy. Results: In-hospital morbidity was similar in both groups. T status prior to administration of chemoradiotherapy correlated with survival in the group with residual cancer (P=0.010), but this relationship was not significant in the group with recurrent cancer (P=0.635). On the other hand, pathological T status showed a significant correlation with survival in both the residual (P<0.001) and recurrent groups (P=0.001). Patients with T3 disease in the recurrent group showed better survival, similar to T0-2 patients, while worse survival was demonstrated in the residual group. In the recurrent group, N status before chemoradiotherapy did not correlate with survival (P=0.895). Conclusions: Patients with residual cancer would have good prognosis by salvage esophagectomy in cases in which the cancer had not invaded to the adventitia at the time of chemoradiotherapy and surgery. Conversely, patients whose cancer was recurrent might benefit from salvage surgery if the cancer appears to be resectable. T and N status before chemoradiotherapy are not important factors in consideration of salvage esophagectomy in cases of recurrent cancer.

  50. Curative resection of advanced esophageal cancer with metachronous stage IV breast cancer: A case report. International-journal Peer-reviewed

    Yusuke Gokon, Tadashi Sakurai, Fumiyoshi Fujishima, Yusuke Taniyama, Takahiro Heishi, Hiroshi Okamoto, Shota Maruyama, Hirotaka Ishida, Yu Onodera, Hironobu Sasano, Takashi Kamei

    International journal of surgery case reports　45　133-137　2018

    DOI： 10.1016/j.ijscr.2018.03.022 　

    More details Close

    INTRODUCTION: Recent studies have shown the safety and efficacy of curative resection of esophageal cancer with multiple primary cancers. However, our literature search revealed no curative surgery cases for esophageal cancer in patients with multiple primary cancers with distant metastasis. CASE PRESENTATION: A 75-year-old woman visited our hospital with dysphagia. She had a history of breast cancer with multiple bone metastasis. Esophagogastroduodenoscopy revealed a circumferential mass in the upper intrathoracic esophagus. Histopathological examination of the biopsy showed squamous cell carcinoma. Other imaging findings revealed multiple nodules in the liver. The nodules were thought to have originated from the breast, but metastasis of esophageal cancer was considered a possibility. Intraoperative frozen sections of the liver and peritoneal nodules showed adenocarcinoma. Thoracoscopic esophagectomy was then performed. Following surgery, the patient received fulvestrant therapy, followed by capecitabine therapy, and the liver tumors decreased in size. She is currently alive after 1.5 years of the surgery without local recurrence of esophageal cancer. DISCUSSION: Although the patient had metastatic breast cancer, her relapse-free interval of 20 years and good response to hormone therapy for 15 years were favorable prognostic factors. Her life expectancy was estimated to be a few years and surgery was performed. CONCLUSION: Curative resection could be considered for patients with esophageal cancer who have an additional cancer with distant metastasis when the prognosis of the additional cancer is not poor.

  51. 手術検体を使用した肺神経内分泌腫瘍の予後規定因子に関する検討

    岡 直美, 笠島 敦子, 石田 裕嵩, 桜田 晃, 櫻田 潤子, 鈴木 博義, 亀谷 徹, 石川 雄一, 岡田 克典, 笹野 公伸

    日本病理学会会誌　106　(1)　278-279　2017/03

    Publisher: (一社)日本病理学会

    ISSN： 0300-9181

  52. Charcot-Marie-Tooth diseaseに合併した食道神経鞘腫の1例 Peer-reviewed

    今野 卓朗, 藤島 史喜, 石田 裕嵩, 伊東 賢, 小澤 洋平, 手島 仁, 櫻井 直, 中野 徹, 亀井 尚, 笹野 公伸

    日本消化器外科学会雑誌　49　(11)　1059-1065　2016/11

    Publisher: (一社)日本消化器外科学会

    ISSN： 0386-9768

    eISSN： 1348-9372

  53. Estrogen receptor β in Merkel cell carcinoma: its possible roles in pathogenesis. International-journal Peer-reviewed

    Abdullah Azmahani, Yasuhiro Nakamura, Hirotaka Ishida, Keely M McNamara, Taku Fujimura, Takahiro Haga, Akira Hashimoto, Setsuya Aiba, Hironobu Sasano

    Human pathology　56　128-33　2016/10

    DOI： 10.1016/j.humpath.2016.06.005 　

    More details Close

    Sex steroids have been postulated to influence skin development and functions as well as its pathogenesis. MCC occurs in both sexes; however, the specific differences in pathogenesis among sexes have yet to be conclusively defined. The detailed status of sex steroid receptors (AR, PRA and PRB, and ERα, ERβ) are also unknown in MCC patients. We first immunolocalized sex steroid receptors and compared the results with immunolocalization of relevant transcription factors including SOX2, FOXA1, and Bcl-2 and Ki-67 in 18 cases of MCCs. AR, PRA, PRB, ERα, ERβ, Bcl-2, SOX2, and FOXA1 immunoreactivity was evaluated by using the modified H score method, and Ki-67 was quantified using labeling index. ERβ immunoreactivity was markedly present in all the cases of MCC examined, with relatively weak immunoreactivity of ERα, AR, PRA, and PRB. The status of ERβ immunoreactivity was also significantly correlated with Ki-67 labeling index and Bcl-2 score. These results demonstrated that ERβ could be associated with regulation of both cell proliferation and apoptosis in MCCs.

  54. 食道扁平上皮癌に関する原発腫瘍とリンパ節におけるnestin発現状況の比較(Comparison of Nestin status in primary tumor and lymph node for esophageal squamous cell carcinoma) Peer-reviewed

    今野 卓朗, 藤島 史喜, 永井 友仁, 中村 保宏, 笠島 敦子, 石田 裕嵩, 伊東 賢, 亀井 尚, 渡辺 みか, 笹野 公伸

    日本病理学会会誌　105　(1)　491-491　2016/04

    Publisher: (一社)日本病理学会

    ISSN： 0300-9181

  55. Neuroendocrine Neoplasms of the Pancreas and the Lungs: Potential Differences in Morphological Characteristics and Cell Cycle Regulation

    Hirotaka Ishida

    LABORATORY INVESTIGATION　2016

  56. Neuroendocrine Neoplasms of the Pancreas and the Lungs: Potential Differences in Morphological Characteristics and Cell Cycle Regulation

    Hirotaka Ishida

    MODERN PATHOLOGY　2016

  57. Schwannoma of the esophagus discovered while examining charcot-marie-tooth disease Peer-reviewed

    Takuro Konno, Fumiyoshi Fujishima, Hirotaka Ishida, Ken Ito, Yohei Ozawa, Jin Teshima, Tadashi Sakurai, Toru Nakano, Takashi Kamei, Hironobu Sasano

    Japanese Journal of Gastroenterological Surgery　49　(11)　1059-1065　2016

    Publisher: Japanese Society of Gastroenterological Surgery

    DOI： 10.5833/jjgs.2015.0225 　

    ISSN： 1348-9372 0386-9768

  58. Comparison of 4 cases of esophageal basaloid squamous carcinoma treated with adjuvant chemotherapy and 21 cases treated without adjuvant chemotherapy: A clinicopathological study Peer-reviewed

    Takuro Konno, Fumiyoshi Fujishima, Hirotaka Ishida, Ken Ito, Yohei Ozawa, Tadashi Sakurai, Tohru Nakano, Takashi Kamei, Hironobu Sasano

    Japanese Journal of Gastroenterological Surgery　49　(10)　963-970　2016

    Publisher: Japanese Society of Gastroenterological Surgery

    DOI： 10.5833/jjgs.2015.0196 　

    ISSN： 1348-9372 0386-9768

    eISSN： 1348-9372

  59. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. International-journal Peer-reviewed

    Yohei Ozawa, Yasuhiro Nakamura, Fumiyoshi Fujishima, Saulo J A Felizola, Kenichiro Takeda, Hiroshi Okamoto, Ken Ito, Hirotaka Ishida, Takuro Konno, Takashi Kamei, Go Miyata, Noriaki Ohuchi, Hironobu Sasano

    BMC cancer　15　451-451　2015/06/03

    DOI： 10.1186/s12885-015-1450-3 　

    More details Close

    BACKGROUND: c-Met is widely known as a poor prognostic factor in various human malignancies. Previous studies have suggested the involvement of c-Met and/or its ligand, hepatocyte growth factor (HGF), in esophageal squamous cell carcinoma (ESCC), but the correlation between c-Met status and clinical outcome remains unclear. Furthermore, the identification of a novel molecular therapeutic target might potentially help improve the clinical outcome of ESCC patients. METHODS: The expression of c-Met and HGF was immunohistochemically assessed in 104 surgically obtained tissue specimens. The correlation between c-Met/HGF expression and patients' clinicopathological features, including survival, was evaluated. We also investigated changes in cell functions and protein expression of c-Met and its downstream signaling pathway components under treatments with HGF and/or c-Met inhibitor in ESCC cell lines. RESULTS: Elevated expression of c-Met was significantly correlated with tumor depth and pathological stage. Patients with high c-Met expression had significantly worse survival. In addition, multivariate analysis identified the high expression of c-Met as an independent prognostic factor. Treatment with c-Met inhibitor under HGF stimulation significantly inhibited the invasive capacity of an ESCC cell line with elevated c-Met mRNA expression. Moreover, c-Met and its downstream signaling inactivation was also detected after treatment with c-Met inhibitor. CONCLUSIONS: The results of our study identified c-Met expression as an independent prognostic factor in ESCC patients and demonstrated that c-Met could be a potential molecular therapeutic target for the treatment of ESCC with elevated c-Met expression.

  60. 腸型肺腺癌が原発と診断し得た癌性リンパ管症で化学療法が奏効し長期生存を得た1例 Peer-reviewed

    石田 裕嵩, 横田 憲一, 鈴木 由佳, 遠藤 悦子, 小笠原 弘之, 小坂 真吉, 峯岸 道人, 岩根 尊, 横山 成邦, 大友 浩志, 笹野 公伸

    癌と化学療法　42　(3)　371-374　2015/03

    Publisher: (株)癌と化学療法社

    ISSN： 0385-0684

  61. Decreased expression of ARID1A contributes to infiltrative growth of esophageal squamous cell carcinoma. Peer-reviewed

    Yohei Ozawa, Yasuhiro Nakamura, Fumiyoshi Fujishima, Saulo J A Felizola, Kenichiro Takeda, Hiroshi Okamoto, Ken Ito, Hirotaka Ishida, Takuro Konno, Takashi Kamei, Noriaki Ohuchi, Hironobu Sasano

    The Tohoku journal of experimental medicine　235　(3)　185-91　2015/03

    DOI： 10.1620/tjem.235.185 　

    More details Close

    The clinical outcome for esophageal squamous cell carcinoma (ESCC) patients is often poor because of the invasive nature of this tumor type. AT-rich interactive domain 1A (ARID1A) functions as a tumor suppressor, and its gene mutation has been reported in various human malignancies. ARID1A is a non-catalytic subunit of the SWItch/Sucrose Non Fermentable (SWI/SNF) chromatin-remodeling complex that regulates gene transcription. Decreased expression of ARID1A protein has been reported to decrease the expression of E-cadherin, an adhesion protein. However, the correlation between ARID1A and E-cadherin expression status in ESCC remains largely unknown. To address this issue, we examined the expression of ARID1A and E-cadherin in tumor specimens excised from 83 ESCC patients using immunohistochemical analysis. The intensity of the ARID1A immunoreactivity was significantly lower in tumors with a growth pattern characterized by ill-defined borders than that in tumors with an expansive growth pattern having a well-demarcated border or tumors with an intermediate growth pattern. Thus, decreased ARID1A immunoreactivity correlated with infiltrative growth of ESCC. In contrast, E-cadherin status did not correlate with the infiltrative growth pattern of ESCC. Moreover, ARID1A expression status did not significantly correlate with any of other clinicopathological factors, E-cadherin expression levels, or the clinical outcome of the patients. On the other hand, the patients with tumors expressing low levels of E-cadherin exhibited significantly lower survival rates than those with high expression. In conclusion, reduced ARID1A expression in tumor tissues contributes to infiltrative growth of ESCC, irrespective of E-cadherin expression levels.

  62. [A rare case of lymphangitis carcinomatosa of the lung due to primary pulmonary adenocarcinoma with intestinal differentiation successfully treated with chemotherapy]. Peer-reviewed

    Hirotaka Ishida, Kenichi Yokota, Yuka Suzuki, Etsuko Endo, Hiroyuki Ogasawara, Shinkichi Kosaka, Michito Minegishi, Takeru Iwane, Shigekuni Yokoyama, Hiroshi Otomo, Hironobu Sasano

    Gan to kagaku ryoho. Cancer & chemotherapy　42　(3)　371-4　2015/03

    ISSN： 0385-0684

    More details Close

    We report a rare case of lymphangitis carcinomatosa in a 66-year-old man with a relatively long survival of 18 months following chemotherapy.The patient initially presented with dyspnea and lower abdominal pain.Subsequent colonoscopy detected adenocarcinoma of the descending colon, and computed tomography (CT) demonstrated indications of lymphangitis carcinomatosa of the lung.Therefore, the patient was diagnosed with pulmonary metastasis due to colon cancer and administered chemotherapy.The performance status (PS) of patients with lymphangitis carcinomatosa is usually dismal.This patient's PS was also poor, but dyspnea markedly improved following chemotherapy, and a subsequent CT revealed disappearance of radiological findings of lymphangitis carcinomatosa.However, subsequent immunocytochemistry analysis using the cell transfer method in bronchoalveolar lavage fluid specimens revealed diffuse positivity for cytokeratin (CK) 7, while the colon carcinoma was negative for CK7.The difference in CK7 immunoreactivity between the bronchoalveolar lavage fluid and biopsy specimen of the colon indicated that the lymphangitis carcinomatosa in this patient could be reasonably postulated to be caused by a synchronous primary pulmonary adenocarcinoma with intestinal differentiation.However, an autopsy could not be performed to test this hypothesis.

  63. 術後横隔膜ヘルニアによりイレウスを繰り返した食道癌の1例 Peer-reviewed

    石田 裕嵩, 横山 成邦, 大友 浩志, 横田 憲一

    日本臨床外科学会雑誌　74　(8)　2123-2127　2013/08

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

Show all ︎Show first 5

Misc. 205

  1. シニアからの提言:若手に伝えたい、ベテラン消化器病・内視鏡医の心に残る症例・研究 小児食道アカラシア症に対する経口内視鏡的筋層切開術(POEM)の治療成績

    佐藤 千晃, 石田 喬之, 丸山 大貴, 邑並 祐人, 安藤 涼平, 氏家 直人, 石田 裕嵩

    日本消化器病学会東北支部例会・日本消化器内視鏡学会東北支部例会プログラム・抄録集　220回・175回　73-73　2026/02

    Publisher: 日本消化器病学会-東北支部

  2. 消化器疾患の継往開来 食道アカラシア治療における継往開来

    石田 裕嵩, 佐藤 千晃, 岡本 宏史, 氏家 直人, 安藤 涼平, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部例会・日本消化器内視鏡学会東北支部例会プログラム・抄録集　220回・175回　94-94　2026/02

    Publisher: 日本消化器病学会-東北支部

  3. 消化器疾患の継往開来 当科における内視鏡的逆流防止粘膜切除術(ARMS)の施行経験

    安藤 涼平, 佐藤 千晃, 氏家 直人, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部例会・日本消化器内視鏡学会東北支部例会プログラム・抄録集　220回・175回　94-94　2026/02

    Publisher: 日本消化器病学会-東北支部

  4. 診療科横断的な消化器病診療の現状と課題 多診療科連携による食道癌治療の最適化 食道疾患カンファレンスの取り組み

    氏家 直人, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 土谷 祐馬, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部例会・日本消化器内視鏡学会東北支部例会プログラム・抄録集　220回・175回　112-112　2026/02

    Publisher: 日本消化器病学会-東北支部

  5. 術後連日の血中CRP濃度から検討した,低侵襲食道切除におけるCRP高値の予後不良因子としての意義

    邑並 祐人, 石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 亀井 尚

    外科と代謝・栄養　59　(6)　169-176　2025/12

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  6. 診断に長期間を要し膿胸を併発した小児期発症食道アカラシアの1例

    佐々木 郁, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 亀井 尚

    日本小児科学会雑誌　129　(11)　1399-1399　2025/11

    Publisher: (公社)日本小児科学会

    ISSN： 0001-6543

    eISSN： 2760-3180

  7. 食道外科における縫合不全対策 食道がん術後の縫合不全予防を目指した栄養療法と縫合不全対策

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 氏家 直人, 安藤 涼平, 土谷 祐馬, 押切 裕之, 海野 倫明, 亀井 尚

    日本外科感染症学会雑誌　22　(1)　172-172　2025/10

    Publisher: (一社)日本外科感染症学会

    ISSN： 1349-5755

    eISSN： 2434-0103

  8. こだわってもこだわりすぎない臨機応変な左反回神経リンパ節郭清

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 氏家 直人, 安藤 涼平, 國光 敦, 土谷 祐馬, 富樫 尭文, 亀井 尚

    日本胸部外科学会定期学術集会　78回　EMO1-9　2025/10

    Publisher: (一社)日本胸部外科学会

  9. 進行胸部食道癌の大血管・気道浸潤または損傷例に対する対処～あの時どうすべきだったか? 心筋との強い癒着・浸潤によりR2切除となった陽子線治療後の進行食道癌症例

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 氏家 直人, 安藤 涼平, 土谷 祐馬, 押切 裕之, 亀井 尚

    日本胸部外科学会定期学術集会　78回　CDWS2-3　2025/10

    Publisher: (一社)日本胸部外科学会

  10. 胸腔鏡/ロボット支援下食道切除術の普及に伴う開胸術教育の課題と当科の取り組み

    佐藤 千晃, 土谷 祐馬, 氏家 直人, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 亀井 尚

    日本胸部外科学会定期学術集会　78回　EMO6-5　2025/10

    Publisher: (一社)日本胸部外科学会

  11. 食道外科医からみた気管分岐部周囲のリンパ節郭清

    谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 氏家 直人, 安藤 涼平, 土谷 祐馬, 海野 倫明, 亀井 尚

    日本胸部外科学会定期学術集会　78回　EMO8-4　2025/10

    Publisher: (一社)日本胸部外科学会

  12. 縫合不全の対応と難治例に対する再建手技 当科における胃管再建の術中～術後管理における工夫/消化管再建に難渋した症例

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 亀井 尚

    日本胸部外科学会定期学術集会　78回　EPD1-1　2025/10

    Publisher: (一社)日本胸部外科学会

  13. 再発食道癌に対するPDT臨床導入10周年シンポジウム 食道癌CRT後の遺残・再発に対するsalvage治療法の比較 OPE vs PDT

    佐藤 千晃, 富樫 堯史, 土谷 祐馬, 安藤 涼平, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 海野 倫明, 亀井 尚

    日本レーザー医学会誌　46　(3)　242-242　2025/09

    Publisher: (NPO)日本レーザー医学会

    ISSN： 0288-6200

    eISSN： 1881-1639

  14. 消化器内視鏡の進展とWell-being社会への貢献:消化管疾患の早期発見と診断の重要性 食道アカラシアの早期発見を目指して アカラシア診断における上部消化管内視鏡検査のピットフォール

    氏家 直人, 邑並 祐人, 國光 敦, 石田 裕嵩, 佐藤 千晃

    日本消化器内視鏡学会東北支部例会　174回　55-55　2025/07

    Publisher: 日本消化器内視鏡学会-東北支部

  15. 【ロボット食道癌手術,メリットと中長期成績】ロボット支援食道切除術における安全な教育と短期および長期成績

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 氏家 直人, 海野 倫明, 亀井 尚

    癌の臨床　69　(3)　101-106　2025/07

    Publisher: (株)篠原出版新社

    ISSN： 0021-4949

  16. 食道がん手術における再建法を考える レーザードップラー血流計/酸素飽和度イメージングを用いた胃管評価の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 篠崎 康晴, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　27-27　2025/06

    Publisher: (NPO)日本食道学会

  17. 食道扁平上皮癌の治療前臨床診断の精度 FDG-PET Maximum Intensity Projection画像による食道癌リンパ節転移予測AIモデル作成

    丸山 大貴, 高浪 健太郎, 高屋 英知, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 谷山 裕亮, 高瀬 圭, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　32-32　2025/06

    Publisher: (NPO)日本食道学会

  18. 食道癌CRT後のT1遺残・再発例に対する救済治療の選択 食道癌CRT後の遺残・再発に対するsilvage治療法の比較検討 OPE vs PDT vs ESD

    佐藤 千晃, 佐々木 郁, 國光 敦, 高橋 洵, 安藤 涼平, 篠崎 康晴, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　41-41　2025/06

    Publisher: (NPO)日本食道学会

  19. 安全かつ低侵襲な救済手術に向けて サルベージ食道切除術の至適郭清範囲と治療成績の検討

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 佐々木 郁, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　51-51　2025/06

    Publisher: (NPO)日本食道学会

  20. ロボット手術と胸腔鏡手術の長期成績 ロボット支援食道切除術の中・長期成績における有効性の検討

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 佐々木 郁, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　55-55　2025/06

    Publisher: (NPO)日本食道学会

  21. 食道がんにおけるOligoMetastatic Diseaseへの新たな挑戦 食道扁平上皮癌根治切除後のOligometastasis症例に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 篠崎 康晴, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　81-81　2025/06

    Publisher: (NPO)日本食道学会

  22. cT3br-T4食道癌における非R0切除のリスク因子の検討

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　156-156　2025/06

    Publisher: (NPO)日本食道学会

  23. 食道癌治療における生体電気インピーダンス法による体組成分析の有用性の検討

    高橋 洵, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 篠崎 康晴, 國光 敦, 佐々木 郁, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　164-164　2025/06

    Publisher: (NPO)日本食道学会

  24. 食道癌術後adjuvant Nivolumabの中期成績と今後への展望

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 國光 敦, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　182-182　2025/06

    Publisher: (NPO)日本食道学会

  25. 維持血液透析患者に対する胸腔鏡下食道切除術5例の検討

    佐々木 郁, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 篠崎 康晴, 高橋 洵, 國光 敦, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　215-215　2025/06

    Publisher: (NPO)日本食道学会

  26. 食道切除術中における胃管血流測定値と吻合部狭窄発生率に関する検討

    佐藤 千晃, 佐々木 郁, 篠崎 康晴, 國光 敦, 高橋 洵, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　289-289　2025/06

    Publisher: (NPO)日本食道学会

  27. 咽喉食摘後の胸部食道癌に対してロボット支援食道切除術を施行した1例

    谷地 涼介, 谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　312-312　2025/06

    Publisher: (NPO)日本食道学会

  28. 切除不能局所進行食道癌に対する食道ステント留置術の治療成績

    邑並 祐人, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 國光 敦, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　79回　355-355　2025/06

    Publisher: (NPO)日本食道学会

  29. ロボット食道癌手術の手技,メリットと中長期成績 ロボット支援食道切除術における安全な教育と短期および長期成績

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　SY-2　2025/04

    Publisher: (一社)日本外科学会

  30. 外科医が行うマイクロバイオーム研究 消化器癌に対する疾患横断的なマイクロバイオーム研究

    小澤 洋平, 唐澤 秀明, 青木 修一, 濱田 健志, 岡本 宏史, 福田 真嗣, 曽我 朋義, 谷山 裕亮, 佐藤 千晃, 石田 裕嵩, 本橋 ほづみ, 阿部 高明, 大沼 忍, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　SY-5　2025/04

    Publisher: (一社)日本外科学会

  31. 食道癌NACの現状と今後 76歳以上の高齢食道扁平上皮癌患者へのNAC施行の意義の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 篠崎 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　WS-8　2025/04

    Publisher: (一社)日本外科学会

  32. 高度進行食道胃接合部腺癌に対する導入化学療法後切除症例の検討

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　SF-2　2025/04

    Publisher: (一社)日本外科学会

  33. 食道癌組織中のF.nucleatumの分布に関する病理組織学的検討

    東本 郁, 石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 藤島 史喜, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　SF-2　2025/04

    Publisher: (一社)日本外科学会

  34. 当科における腹腔鏡下食道裂孔ヘルニア手術の臨床学的検討と手術時の工夫

    安藤 涼平, 佐藤 千晃, 佐々木 郁, 高橋 洵, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　SF-3　2025/04

    Publisher: (一社)日本外科学会

  35. 小児・若年者食道アカラシアに対する経口内視鏡的筋層切開術の治療成績

    佐藤 千晃, 佐々木 郁, 高橋 洵, 安藤 涼平, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　SF-6　2025/04

    Publisher: (一社)日本外科学会

  36. 体成分分析による食道癌術前化学療法に対する認容性の予測

    高橋 洵, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 佐々木 郁, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　SF-6　2025/04

    Publisher: (一社)日本外科学会

  37. 食道扁平上皮癌におけるxCT発現の意義について

    茂住 武尊, 原田 成美, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 高橋 洵, 佐々木 郁, 和田 基, 大沼 忍, 海野 倫明, 石田 孝宣, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　PS-8　2025/04

    Publisher: (一社)日本外科学会

  38. 左半腹臥位CTを用いた胸腔鏡下食道切除術におけるポート配置の検討

    丸山 大貴, 高浪 健太郎, 外山 由貴, 八嶋 嘉之, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 佐々木 郁, 高瀬 圭, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　PS-4　2025/04

    Publisher: (一社)日本外科学会

  39. 食道癌に対するPDTの治療成績および安全性の検討

    邑並 祐人, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　125回　PS-5　2025/04

    Publisher: (一社)日本外科学会

  40. 【見せましょう! 外科治療における栄養療法の底力】食道外科における栄養療法 食道癌周術期の栄養療法

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 小林 千沙, 亀井 尚

    臨床外科　80　(4)　446-450　2025/04

    Publisher: (株)医学書院

    ISSN： 0386-9857

    eISSN： 1882-1278

  41. 【消化器外科における周術期栄養療法】総論 サルコペニア・フレイルと栄養療法

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 亀井 尚

    手術　79　(5)　753-759　2025/04

    Publisher: 金原出版(株)

    ISSN： 0037-4423

  42. 私のロボット手術:手術のコツと守るべきこと 安全で効率的なロボット支援食道手術のために

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 丸山 大貴, 亀井 尚

    日本気管食道科学会会報　76　(2)　114-114　2025/04

    Publisher: (NPO)日本気管食道科学会

    ISSN： 0029-0645

    eISSN： 1880-6848

  43. 20歳以下の食道アカラシア症に対するPOEMの治療成績

    佐藤 千晃, 丸山 大貴, 國光 敦, 安藤 涼平, 石田 裕嵩

    Gastroenterological Endoscopy　67　(Suppl.1)　735-735　2025/04

    Publisher: (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  44. 当科におけるバルーン拡張後のアカラシアに対するPOEMの検討

    丸山 大貴, 佐藤 千晃, 安藤 涼平, 石田 裕嵩, 國光 敦

    Gastroenterological Endoscopy　67　(Suppl.1)　736-736　2025/04

    Publisher: (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  45. 食道アカラシア・シグモイド型に対するPOEMの治療成績

    石田 裕嵩, 佐藤 千晃, 安藤 涼平

    Gastroenterological Endoscopy　67　(Suppl.1)　736-736　2025/04

    Publisher: (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  46. 食道アカラシアに対するPOEM後の残存胸痛の検討

    邑並 祐人, 佐藤 千晃, 國光 敦, 石田 裕嵩, 安藤 涼平

    Gastroenterological Endoscopy　67　(Suppl.1)　737-737　2025/04

    Publisher: (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  47. 質の高い消化管疾患診療の実践と未来への提言 食道アカラシアに対する経口内視鏡的筋層切開術 導入と治療成績

    石田 裕嵩, 佐藤 千晃, 安藤 涼平

    日本消化器内視鏡学会東北支部例会　173回　72-72　2025/02

    Publisher: 日本消化器内視鏡学会-東北支部

  48. 消化器疾患診療の現状と近未来・上部消化管・その他の部 局所遺残再発食道癌に対するPDTの現状と今後の展望

    八嶋 嘉之, 佐藤 千晃, 邑並 祐人, 安藤 涼平, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部例会プログラム・抄録集　218回　98-98　2025/02

    Publisher: 日本消化器病学会-東北支部

  49. 診断に長期間を要し膿胸を併発した小児期発症食道アカラシアの一例

    佐々木 郁, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 高橋 洵, 國光 敦, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部例会プログラム・抄録集　218回　147-147　2025/02

    Publisher: 日本消化器病学会-東北支部

  50. ロボット支援胸腔鏡下食道切除での術中操作の留意点

    岡本宏史, 谷山裕亮, 佐藤千晃, 小澤洋平, 石田裕嵩, 氏家直人, 安藤涼平, 國光敦, 土谷祐馬, 大沼忍, 海野倫明, 亀井尚

    日本内視鏡外科学会総会(Web)　38th　2025

  51. T4食道癌への挑戦-内視鏡下手術による安全性と根治性の両立を目指して-

    氏家直人, 谷山裕亮, 佐藤千晃, 岡本宏史, 小澤洋平, 石田裕嵩, 安藤涼平, 國光敦, 土谷祐馬, 大沼忍, 海野倫明, 亀井尚

    日本内視鏡外科学会総会(Web)　38th　2025

  52. 通過障害をきたす食道裂孔ヘルニアに対する外科治療成績

    佐藤千晃, 富樫堯史, 土谷祐馬, 國光敦, 氏家直人, 石田裕嵩, 小澤洋平, 岡本宏史, 谷山裕亮, 大沼忍, 海野倫明, 亀井尚

    日本消化器病学会東北支部例会誌　219th　2025

  53. 食道外科医が知っておきたい肺静脈の解剖、他領域の先生に知っていただきたい食道の取扱い

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 篠崎 康晴, 安藤 涼平, 高橋 洵, 亀井 尚

    日本胸部外科学会定期学術集会　77回　CDP3-5　2024/11

    Publisher: (一社)日本胸部外科学会

  54. 食道癌術後縫合不全、胃管壊死の早期診断と治療 低侵襲食道切除後における血中CRP/PCT濃度の縫合不全診断マーカーとしての意義

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 篠崎 康晴, 亀井 尚

    日本胸部外科学会定期学術集会　77回　EPD1-4　2024/11

    Publisher: (一社)日本胸部外科学会

  55. 胸部食道癌におけるcStage IIIA(食道癌取扱い規約第12版)の妥当性の検証 食道癌における旧規約から新規約への再分類とcStage IIIAにおける手術治療成績の検討

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 大沼 忍, 海野 倫明, 亀井 尚

    日本胸部外科学会定期学術集会　77回　EPD3-5　2024/11

    Publisher: (一社)日本胸部外科学会

  56. Staged surgeryの現状 当院における分割手術の現状とその工夫

    篠崎 康晴, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 亀井 尚

    日本胸部外科学会定期学術集会　77回　EWS1-1　2024/11

    Publisher: (一社)日本胸部外科学会

  57. 食道癌手術における術中副損傷への対応、開胸移行 胸腔鏡下食道切除後心タンポナーデをきたした2例

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 亀井 尚

    日本胸部外科学会定期学術集会　77回　EVW-3　2024/11

    Publisher: (一社)日本胸部外科学会

  58. プロテインS欠乏症患者の食道・胃全摘術後の再建において苦慮した一例

    富樫 尭史, 谷山 裕亮, 岡本 宏史, 黒沢 是之, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 石田 孝宣, 海野 倫明, 亀井 尚

    日本胸部外科学会定期学術集会　77回　ECPA-2　2024/11

    Publisher: (一社)日本胸部外科学会

  59. ロボット支援食道切除術の現状 合併症と教育体制

    佐藤 千晃, 高橋 洵, 篠崎 康晴, 安藤 涼平, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 海野 倫明, 亀井 尚

    日本胸部外科学会定期学術集会　77回　EOP2-1　2024/11

    Publisher: (一社)日本胸部外科学会

  60. 食道癌CRT/RT後の局所遺残再発に対するPDTの治療成績

    邑並 祐人, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平

    日本胸部外科学会定期学術集会　77回　EOP2-9　2024/11

    Publisher: (一社)日本胸部外科学会

  61. 食道癌患者の呼気における超硫黄代謝解析

    朝光 世志, 小澤 洋平, 緒方 星陵, 岡本 宏史, 吉武 淳, 松永 哲郎, 谷山 裕亮, 佐藤 千晃, 石田 裕嵩, 阿部 高明, 亀井 尚, 赤池 孝章

    日本生化学会大会プログラム・講演要旨集　97回　[3P-129]　2024/11

    Publisher: (公社)日本生化学会

  62. 超高齢者に対する進行消化器癌外科手術の在り方 80歳以上の高齢者食道切除の短期/長期成績の検討

    石田 裕嵩, 谷山 裕亮, 亀井 尚

    日本消化器外科学会雑誌　57　(Suppl.2)　141-141　2024/11

    Publisher: (一社)日本消化器外科学会

    ISSN： 0386-9768

    eISSN： 1348-9372

  63. 食道癌化学放射線治療後の再発に対する治療戦略 光線力学的療法とサルベージ食道切除術の治療成績の比較検討

    佐藤 千晃, 高橋 洵, 篠崎 康晴, 安藤 涼平, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　85　(増刊)　S152-S152　2024/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  64. 食道亜全摘における胃管以外の再建臓器に対する検討 有茎空腸か結腸再建か

    篠崎 康晴, 小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 安藤 涼平, 高橋 洵, 亀井 尚

    日本臨床外科学会雑誌　85　(増刊)　S153-S153　2024/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  65. 高齢者食道癌患者の術後肺炎が長期成績に与える影響とその対策

    高橋 洵, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　85　(増刊)　S176-S176　2024/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  66. ロボット支援下食道切除の術後短期成績と周術期栄養指標の推移 胸腔鏡下食道切除術との比較検討

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 大沼 忍, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　85　(増刊)　S182-S182　2024/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  67. 周術期の栄養管理の核心に迫る!～静脈栄養の未来は? 食道癌患者における年齢・栄養状態・サルコペニアによる術後栄養状態の変化と栄養管理の注意点

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 篠崎 康晴, 八嶋 嘉之, 三浦 琢磨, 大沼 忍, 海野 倫明, 亀井 尚

    外科と代謝・栄養　58　(3)　58-58　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  68. 外科栄養における未来の基礎研究 骨格筋減少の血液マーカーとしてのマイオカインの有用性と治療効果への影響

    邑並 祐人, 小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 篠崎 康晴, 八嶋 嘉之, 三浦 琢磨, 亀井 尚

    外科と代謝・栄養　58　(3)　64-64　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  69. 経腸栄養で管理中の低亜鉛血症に対して亜鉛補充の継続により汎血球減少を呈した低銅血症の一例

    篠崎 康晴, 小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩

    外科と代謝・栄養　58　(3)　80-80　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  70. 低侵襲食道切除後における血中CRP濃度の炎症/予後予測マーカーとしての意義

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 篠崎 康晴, 海野 倫明, 亀井 尚

    外科と代謝・栄養　58　(3)　86-86　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  71. 消化管疾患に対する内視鏡診療の進歩 当科におけるバルーン拡張後のアカラシアに対するPOEMの検討

    丸山 大貴, 佐藤 千晃, 安藤 涼平, 石田 裕嵩, 亀井 尚

    日本消化器内視鏡学会東北支部例会　172回　67-67　2024/07

    Publisher: 日本消化器内視鏡学会-東北支部

  72. 食道扁平上皮癌におけるNACの有効性を予測する内視鏡画像と臨床情報を用いた深層学習モデルの開発

    三浦 琢磨, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 篠崎 康晴, 八嶋 嘉之, 石田 喬之, 亀井 尚

    日本消化器外科学会総会　79回　638-639　2024/07

    Publisher: (一社)日本消化器外科学会

  73. 当科における食道胃接合部癌の現状と治療成績の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 小関 健, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　79回　901-902　2024/07

    Publisher: (一社)日本消化器外科学会

  74. 低侵襲食道切除術後の骨格筋量維持と栄養状態改善にむけての取り組みと課題

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　79回　1202-1202　2024/07

    Publisher: (一社)日本消化器外科学会

  75. 当院での術前治療+食道切除後の術後補助ニボルマブ療法の現状

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 篠崎 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　79回　1888-1889　2024/07

    Publisher: (一社)日本消化器外科学会

  76. 食道癌術後再発の要因と対策 食道癌根治切除後のOligometastasis症例に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 篠崎 康晴, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　37-37　2024/07

    Publisher: (NPO)日本食道学会

  77. 食道癌サルベージ・コンバージョン手術の術式選択とアウトカム 当科におけるsalvage食道切除術の治療戦略とその成績

    谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 篠崎 康晴, 安藤 涼平, 高橋 洵, 海野 倫明, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　49-49　2024/07

    Publisher: (NPO)日本食道学会

  78. AIが拓く未来の食道疾患の診断と治療 深層学習を用いた食道癌リンパ節転移診断

    篠崎 康晴, 石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　76-76　2024/07

    Publisher: (NPO)日本食道学会

  79. 当院における喉頭温存を目指した頸部食道癌に対する根治的放射線療法の成績

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 八嶋 嘉之, 篠崎 康晴, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　97-97　2024/07

    Publisher: (NPO)日本食道学会

  80. 横隔膜上憩室を伴う食道アカラシアに対する経口内視鏡的筋層切開術の有効性

    佐藤 千晃, 三浦 琢磨, 八嶋 嘉之, 篠崎 康晴, 小関 健, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　99-99　2024/07

    Publisher: (NPO)日本食道学会

  81. 食道癌組織中のF.nucleatumの浸潤と局在に関する病理組織学的検討

    東本 郁, 藤島 史喜, 茂住 武尊, 國光 敦, 石田 裕嵩, 小澤 洋平, 谷山 裕亮, 亀井 尚, 鈴木 貴

    日本食道学会学術集会プログラム・抄録集　78回　121-121　2024/07

    Publisher: (NPO)日本食道学会

  82. NRF2活性化型食道扁平上皮がんマウスモデルの作成と解析

    高橋 洵, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 谷山 裕亮, 鈴木 隆史, 山本 雅之, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　141-141　2024/07

    Publisher: (NPO)日本食道学会

  83. 根治切除を目指したT3br・T4食道癌の集学的治療戦略

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 篠崎 康晴, 八嶋 嘉之, 三浦 琢磨, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　177-177　2024/07

    Publisher: (NPO)日本食道学会

  84. 食道裂孔ヘルニアを合併した下咽頭喉頭切除症例に対する手術戦略

    石田 喬之, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 篠崎 康晴, 八嶋 嘉之, 三浦 琢磨, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　240-240　2024/07

    Publisher: (NPO)日本食道学会

  85. 腹腔鏡下噴門形成術後の狭窄に対し有効であった外科的治療の一例

    皆瀬 翼, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 篠崎 康晴, 海野 倫明, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　247-247　2024/07

    Publisher: (NPO)日本食道学会

  86. 外科的治療により救命し得たSBチューブによる食道破裂の一例

    小林 千紗, 谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 篠崎 康晴, 海野 倫明, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　78回　344-344　2024/07

    Publisher: (NPO)日本食道学会

  87. 周術期の栄養管理の核心に迫る!～静脈栄養の未来は? 食道癌患者における年齢・栄養状態・サルコペニアによる術後栄養状態の変化と栄養管理の注意点

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 篠崎 康晴, 八嶋 嘉之, 三浦 琢磨, 大沼 忍, 海野 倫明, 亀井 尚

    外科と代謝・栄養　58　(3)　58-58　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  88. 外科栄養における未来の基礎研究 骨格筋減少の血液マーカーとしてのマイオカインの有用性と治療効果への影響

    邑並 祐人, 小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 篠崎 康晴, 八嶋 嘉之, 三浦 琢磨, 亀井 尚

    外科と代謝・栄養　58　(3)　64-64　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  89. 経腸栄養で管理中の低亜鉛血症に対して亜鉛補充の継続により汎血球減少を呈した低銅血症の一例

    篠崎 康晴, 小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩

    外科と代謝・栄養　58　(3)　80-80　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  90. 低侵襲食道切除後における血中CRP濃度の炎症/予後予測マーカーとしての意義

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 篠崎 康晴, 海野 倫明, 亀井 尚

    外科と代謝・栄養　58　(3)　86-86　2024/07

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  91. 食道裂孔ヘルニア手術により咽喉頭逆流症の改善が得られた一例

    安藤 涼平, 佐藤 千晃, 高橋 洵, 篠崎 康晴, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部例会プログラム・抄録集　217回　87-87　2024/07

    Publisher: 日本消化器病学会-東北支部

  92. 食道癌術後合併症低減のための手術手技・周術期の工夫 食道切除後の再建におけるトラブルへの工夫と対処

    谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 安藤 洋平, 篠崎 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    日本外科系連合学会誌　49　(3)　227-227　2024/05

    Publisher: 日本外科系連合学会

    ISSN： 0385-7883

    eISSN： 1882-9112

  93. ロボット支援食道手術における短中期成績 ロボット支援下食道切除における短期・中期成績の検討と今後への展望

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 八嶋 嘉之, 金淵 佐和, 角掛 純一, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　124回　SY-2　2024/04

    Publisher: (一社)日本外科学会

  94. 食道胃接合部腺癌に対する集学的治療 高度進行食道胃接合部腺癌に対するconversion surgeryも見据えた導入化学療法後切除症例の検討

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 篠崎 康晴, 大沼 忍, 海野 倫明, 石田 孝宣, 亀井 尚

    日本外科学会定期学術集会抄録集　124回　SY-6　2024/04

    Publisher: (一社)日本外科学会

  95. 上部消化管外科におけるロボット手術のトラブルシューティング(ヒヤリハットを含む) ロボット支援低侵襲食道切除術における偶発症

    佐藤 千晃, 角掛 純一, 金淵 佐和, 八嶋 嘉之, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　124回　WS-7　2024/04

    Publisher: (一社)日本外科学会

  96. 最新の嚥下研究と診療 高解像度内圧測定検査を用いた胸部食道癌手術後の嚥下機能の検討

    小関 健, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 金淵 佐和, 邑並 祐人, 布施川 一樹, 亀井 尚

    日本気管食道科学会会報　75　(2)　161-161　2024/04

    Publisher: (NPO)日本気管食道科学会

    ISSN： 0029-0645

    eISSN： 1880-6848

  97. 当科における頸部食道癌治療成績の検討

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 金淵 佐和, 邑並 祐人, 布施川 一樹, 亀井 尚

    日本気管食道科学会会報　75　(2)　s8-s8　2024/04

    Publisher: (NPO)日本気管食道科学会

    ISSN： 0029-0645

    eISSN： 1880-6848

  98. 食道癌放射線療法後再発に対し光線力学療法にて完全寛解が得られた1例

    八嶋 嘉之, 邑並 祐人, 石田 裕嵩, 小関 健, 佐藤 千晃

    日本消化器内視鏡学会東北支部例会　171回　96-96　2024/02

    Publisher: 日本消化器内視鏡学会-東北支部

  99. 230例の経験から検討する食道アカラシアの早期診断のための工夫

    邑並 祐人, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 八嶋 嘉之, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部例会プログラム・抄録集　216回　93-93　2024/02

    Publisher: 日本消化器病学会-東北支部

  100. 腹部救急・重症患者診療における代謝栄養管理を考える 当院での食道癌周術期代謝栄養管理の取り組み 術後合併症低減・回復促進・予後向上を目指して

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 篠崎 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    日本腹部救急医学会雑誌　44　(2)　301-301　2024/02

    Publisher: (一社)日本腹部救急医学会

    ISSN： 1340-2242

    eISSN： 1882-4781

  101. 胃管癌に対する治療成績

    佐藤 千晃, 八嶋 嘉之, 金淵 佐和, 角掛 純一, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本胃癌学会総会記事　96回　384-384　2024/02

    Publisher: (一社)日本胃癌学会

  102. 食道アカラシアに対する経口内視鏡的筋層切開術~導入と治療成績~

    佐藤千晃, 丸山大貴, 高橋洵, 篠崎康晴, 安藤亮平, 石田裕嵩, 小澤洋平, 岡本宏史, 谷山裕亮, 海野倫明, 亀井尚

    日本気管食道科学会総会ならびに学術講演会プログラム・予稿集　75th (CD-ROM)　2024

  103. GLIM基準を用いた食道癌術後患者の栄養診断と患者背景に関する調査

    田口 雄也, 佐々木 まなみ, 小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 亀井 尚

    学会誌JSPEN　6　(Suppl.2)　25-25　2024

    Publisher: (一社)日本栄養治療学会

    eISSN： 2434-4966

  104. 高齢者食道癌患者の周術期プレアルブミンの推移の特徴

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 安藤 涼平, 篠崎 康晴, 高橋 洵, 大沼 忍, 海野 倫明, 亀井 尚

    学会誌JSPEN　6　(Suppl.2)　30-31　2024

    Publisher: (一社)日本栄養治療学会

    eISSN： 2434-4966

  105. 高度進行食道癌に対する低侵襲手術 鏡視下食道切除術を施行したcT3症例の再検討と部位別T3Br症例の短長期成績

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 金淵 佐和, 邑並 祐人, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　28　(7)　144-144　2023/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  106. 腹腔鏡下Nissen噴門形成術後の再々発に対し腹腔鏡下再噴門形成術を施行した1例

    加藤 伸史, 佐藤 千晃, 邑並 祐人, 角掛 純一, 廣瀬 亘, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　28　(7)　632-632　2023/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  107. 難治性胃食道逆流症・食道裂孔ヘルニアに対する外科治療 Up-side down stomachを呈する食道裂孔ヘルニアに対する手術成績

    佐藤 千晃, 邑並 祐人, 金淵 佐和, 小関 健, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　28　(7)　821-821　2023/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  108. 安全な食道切除・再建のための工夫 安全なロボット支援食道切除のために

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 金淵 佐和, 邑並 祐人, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　28　(7)　1070-1070　2023/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  109. 陽子線治療後のサルベージ食道切除5例の検討

    邑並 祐人, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 金淵 佐和, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　28　(7)　2603-2603　2023/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  110. ロボットの特性を活かした右上縦隔リンパ節郭清の工夫とその成績

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　28　(7)　2648-2648　2023/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  111. 周術期感染症と術後早期回復プログラム(ESSENSEとERAS) 患者満足を伴う術後合併症低減・回復促進に向けての食道癌周術期の当院での取り組み

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 篠崎 康晴, 八嶋 嘉之, 亀井 尚

    日本外科感染症学会雑誌　20　(3)　344-344　2023/11

    Publisher: (一社)日本外科感染症学会

    ISSN： 1349-5755

    eISSN： 2434-0103

  112. 食道癌放射線化学療法後の局所遺残再発に対する光線力学療法(PDT)の有効性と安全性

    邑並 祐人, 佐藤 千晃, 谷山 裕亮, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 大沼 忍, 海野 倫明, 亀井 尚

    Gastroenterological Endoscopy　65　(Suppl.2)　1965-1965　2023/10

    Publisher: (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  113. cT3br、cT4局所進行食道癌に対する低侵襲手術の妥当性 局所進行食道癌における食道切除術の手術戦略とその短期および長期成績

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 亀井 尚

    日本胸部外科学会定期学術集会　76回　EVS1-7　2023/10

    Publisher: (一社)日本胸部外科学会

  114. 術野内再発を考える 当科における食道癌根治切除後・術野内再発の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 亀井 尚

    日本胸部外科学会定期学術集会　76回　EWS1-6　2023/10

    Publisher: (一社)日本胸部外科学会

  115. サルベージ手術におけるリンパ節郭清;郭清は必要か Salvage食道切除術の治療成績 予防的リンパ節郭清は必要か

    佐藤 千晃, 邑並 祐人, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 亀井 尚

    日本胸部外科学会定期学術集会　76回　EDB1-4　2023/10

    Publisher: (一社)日本胸部外科学会

  116. 胸腔鏡下に切除した瘻孔形成を伴う食道嚢胞の一例

    宮田 惟, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 大沼 忍, 海野 倫明, 亀井 尚

    日本胸部外科学会定期学術集会　76回　ECPA1-4　2023/10

    Publisher: (一社)日本胸部外科学会

  117. 安全な胸腔鏡下食道切除術習得のためのCadaverトレーニング

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 金淵 佐和, 邑並 祐人, 布施川 一樹, 亀井 尚

    日本胸部外科学会定期学術集会　76回　EP4-1　2023/10

    Publisher: (一社)日本胸部外科学会

  118. 食道癌陽子線治療後のサルベージ手術5例の検討

    邑並 祐人, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 亀井 尚

    日本胸部外科学会定期学術集会　76回　EP10-5　2023/10

    Publisher: (一社)日本胸部外科学会

  119. 食道癌周術期における早期経腸栄養と周術期リハビリテーション介入の効果の検討

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 邑並 祐人, 亀井 尚

    日本胸部外科学会定期学術集会　76回　EP13-6　2023/10

    Publisher: (一社)日本胸部外科学会

  120. 【総論】ロボット支援手術時代の若手消化器外科医の教育 当科におけるロボット支援下食道切除術の治療成績と指導体制

    佐藤 千晃, 加藤 伸史, 小関 健, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　78回　WS2-3　2023/07

    Publisher: (一社)日本消化器外科学会

  121. 【総論】大腸癌以外のoligometastasisに対する集学的治療の現状と課題 食道癌根治切除後のOligometastasis症例に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 加藤 伸史, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　78回　WS5-1　2023/07

    Publisher: (一社)日本消化器外科学会

  122. 80歳以上の高齢者の食道癌根治手術およびリンパ節郭清省略に関する検討

    邑並 祐人, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 加藤 伸史, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　78回　RS7-5　2023/07

    Publisher: (一社)日本消化器外科学会

  123. 胆膵消化管に発生した混合型神経内分泌腫瘍患者における腫瘍組織微小環境の検討

    角掛 純一, 藤島 史喜, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 海野 倫明, 笹野 公伸, 亀井 尚

    日本消化器外科学会総会　78回　P015-5　2023/07

    Publisher: (一社)日本消化器外科学会

  124. 高度進行食道胃接合部腺癌に対する導入化学療法後切除症例の検討

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　78回　P061-4　2023/07

    Publisher: (一社)日本消化器外科学会

  125. 胸腔鏡下に切除した瘻孔形成を伴う食道嚢胞の一例

    宮田 惟, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　78回　P136-2　2023/07

    Publisher: (一社)日本消化器外科学会

  126. 食道癌手術症例におけるBIA法によるサルコペニアの特徴と周術期推移や手術成績に与える影響の検討

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 加藤 伸史, 大沼 忍, 海野 倫明, 亀井 尚

    日本消化器外科学会総会　78回　P217-7　2023/07

    Publisher: (一社)日本消化器外科学会

  127. 胸腔鏡手術における中下縦隔郭清術

    亀井 尚, 谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩

    日本食道学会学術集会プログラム・抄録集　77回　6-6　2023/06

    Publisher: (NPO)日本食道学会

  128. ロボット支援下食道切除術のエビデンス ロボット支援食道切除術における短期および長期成績の検討

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 角掛 純一, 廣瀬 亘, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　8-8　2023/06

    Publisher: (NPO)日本食道学会

  129. 食道アカラシアに対するPOEMと外科手術の長期治療成績 経口内視鏡的筋層切開術とヘラー筋層切開術+噴門形成術の比較(Peroral endoscopic myotomy vs Heller myotomy with fundoplication in our center)

    邑並 祐人, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 角掛 純一, 廣瀬 亘, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　21-21　2023/06

    Publisher: (NPO)日本食道学会

  130. 高齢者・フレイル食道癌患者に対する治療戦略 高齢者の食道癌術後の他病死リスクと予測因子についての検討

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 加藤 伸史, 角掛 純一, 廣瀬 亘, 邑並 祐人, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　53-53　2023/06

    Publisher: (NPO)日本食道学会

  131. 当院で行ったcT1N0M0食道扁平上皮癌に対する手術治療と化学放射線療法の比較検討

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 高橋 紀善, 梅澤 玲, 神宮 啓一, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　132-132　2023/06

    Publisher: (NPO)日本食道学会

  132. cStage IIIB/IVA食道癌に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 加藤 伸史, 角掛 純一, 廣瀬 亘, 邑並 祐人, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　165-165　2023/06

    Publisher: (NPO)日本食道学会

  133. QOLの観点から考える切除不能食道癌に対するステント留置術とバイパス術の比較

    加藤 伸史, 邑並 祐人, 廣瀬 亘, 角掛 純一, 小関 健, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 谷山 裕亮, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　177-177　2023/06

    Publisher: (NPO)日本食道学会

  134. 胸腔鏡下食道切除後に遅発性の心嚢内出血により心タンポナーデを来した1例

    福富 俊明, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　285-285　2023/06

    Publisher: (NPO)日本食道学会

  135. 転移性脳腫瘍切除後に胸部食道原発の腺癌が発覚し、食道切除術を施行した一例

    角掛 純一, 谷山 裕亮, 藤島 史喜, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 加藤 伸史, 海野 倫明, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　77回　291-291　2023/06

    Publisher: (NPO)日本食道学会

  136. 私の手術手技の工夫(胸部) 胸腔鏡下食道癌手術における右胸腔の癒着剥離術の工夫

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 角掛 純一, 廣瀬 亘, 金淵 佐和, 邑並 祐人, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科系連合学会誌　48　(3)　380-380　2023/05

    Publisher: 日本外科系連合学会

    ISSN： 0385-7883

    eISSN： 1882-9112

  137. 当科における若手外科医獲得のための戦略

    谷山 裕亮, 赤松 大二朗, 田中 直樹, 多田 寛, 青木 修一, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　123回　HFT-4　2023/04

    Publisher: (一社)日本外科学会

  138. 頸部食道癌に対するDocetaxel/CDDP/5-FU併用放射線療法の治療成績

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 山内 拓郎, 大沼 忍, 海野 倫明, 石田 孝宣, 亀井 尚

    日本外科学会定期学術集会抄録集　123回　DP-3　2023/04

    Publisher: (一社)日本外科学会

  139. Up-side down stomachを呈する食道裂孔ヘルニアに対する腹腔鏡下食道裂孔ヘルニア修復術の手術成績

    佐藤 千晃, 加藤 伸史, 山内 拓郎, 小関 健, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　123回　DP-7　2023/04

    Publisher: (一社)日本外科学会

  140. 【食道再建のすべて】食道再建術における縫合不全回避のための工夫

    福富 俊明, 岡本 宏史, 石田 裕嵩, 亀井 尚

    消化器外科　46　(2)　167-177　2023/02

    Publisher: (株)へるす出版

    ISSN： 0387-2645

  141. ESSENSEによる周術期管理～わが国におけるESSENSEのさらなる普及を目指して～ 患者満足をともなった術後回復促進に向けて 食道癌周術期の取り組みと成果

    小澤 洋平, 岡本 宏史, 谷山 裕亮, 佐藤 千晃, 石田 裕嵩, 加藤 伸史, 角掛 純一, 廣瀬 亘, 篠崎 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    外科と代謝・栄養　57　(3)　69-69　2023

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  142. 食道癌手術における空腸瘻を用いた早期経腸栄養の効果とリスク因子の検討

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 金淵 佐和, 邑並 祐人, 布施川 一樹, 大沼 忍, 海野 倫明, 亀井 尚

    学会誌JSPEN　5　(Suppl.2)　40-41　2023

    Publisher: (一社)日本栄養治療学会

    eISSN： 2434-4966

  143. Upside down stomachを呈する食道裂孔ヘルニアに対する腹腔鏡下食道裂孔ヘルニア修復術の手技の工夫と治療成績の検討

    佐藤 千晃, 山内 拓郎, 加藤 伸史, 小関 健, 石田 裕嵩, 小澤 洋平, 岡本 宏史, 谷山 裕亮, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　27　(7)　548-548　2022/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  144. 陽子線治療後の再発食道癌に対して胸腔鏡下食道切除術を施行した3例

    茂住 武尊, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　27　(7)　1203-1203　2022/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  145. 胃癌・食道癌に対するロボット支援手術教育の工夫 ロボット支援下食道切除術における次世代への教育

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　27　(7)　1278-1278　2022/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  146. 当科の低侵襲食道癌手術における術者育成と術後成績の検討

    石田 裕嵩, 谷山 裕亮, 山内 拓郎, 加藤 伸史, 小関 健, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　27　(7)　1723-1723　2022/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  147. Salvage手術に対しロボット支援下食道切除術を施行した4例

    東本 郁, 谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 加藤 伸史, 大沼 忍, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　27　(7)　1983-1983　2022/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  148. 【サルコペニア併存消化器外科手術患者に対する術前・術後栄養管理】サルコペニア併存食道癌患者に対する術前・術後栄養管理とリハビリテーション

    亀井 尚, 小澤 洋平, 谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小関 健, 石田 裕嵩

    外科と代謝・栄養　56　(6)　209-213　2022/12

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  149. 低侵襲手術-どこまでできるか、各領域の適応と限界-内視鏡を駆使した手術 食道癌に対する低侵襲手術の適応と困難症例に対する手技

    亀井 尚, 谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 小関 健, 石田 裕嵩

    日本胸部外科学会定期学術集会　75回　CDVS1-3　2022/10

    Publisher: (一社)日本胸部外科学会

  150. ロボット特有の手技を活かした食道癌手術 食道癌手術におけるロボットの利点と今後の課題

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 亀井 尚

    日本胸部外科学会定期学術集会　75回　EVW1-5　2022/10

    Publisher: (一社)日本胸部外科学会

  151. 食道癌に対するロボット支援下手術の治療成績 ロボット支援下食道切除術の現状と今後への展望

    岡本 宏史, 谷山 裕亮, 佐藤 千晃, 小澤 洋平, 石田 裕嵩, 小関 健, 山内 拓郎, 加藤 伸文, 大沼 忍, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　83　(増刊)　S118-S118　2022/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  152. 集中治療における早期栄養療法開始の実践 食道癌術後におけるICUからの早期経腸栄養の実際と注意点

    小澤 洋平, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 石田 裕嵩, 小関 健, 山内 拓郎, 加藤 伸史, 大沼 忍, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　83　(増刊)　S186-S186　2022/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  153. 当科における80歳以上の食道癌患者に対する手術戦略と成績

    加藤 伸史, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 小関 健, 山内 拓郎, 大沼 忍, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　83　(増刊)　S242-S242　2022/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  154. 食道癌におけるバイオマーカー・予後因子 TXNRD1、HO-1の食道癌術前化学放射線療法患者での治療抵抗性及び予後の指標としての有用性

    赤石 隆二郎, 藤島 史喜, 山内 拓郎, 石田 裕嵩, 福富 俊明, 岡本 宏史, 佐藤 千晃, 谷山 裕亮, 亀井 尚, 笹野 公伸

    日本食道学会学術集会プログラム・抄録集　76回　18-18　2022/09

    Publisher: (NPO)日本食道学会

  155. 食道類基底細胞癌の生検検体における小細胞癌様所見の臨床病理学的意義

    石田 裕嵩, 笠島 敦子, 小関 健, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 谷山 裕亮, 藤島 史喜, 亀井 尚, 笹野 公伸

    日本食道学会学術集会プログラム・抄録集　76回　237-237　2022/09

    Publisher: (NPO)日本食道学会

  156. ロボット支援下食道切除術の問題点の検証と対策

    谷山 裕亮, 岡本 宏史, 佐藤 千晃, 福富 俊明, 小澤 洋平, 小関 健, 石田 裕嵩, 山内 拓郎, 加藤 伸史, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　76回　314-314　2022/09

    Publisher: (NPO)日本食道学会

  157. 食道癌扁平上皮癌の術後早期のプロカルシトニン値が長期予後に与える影響

    福富 俊明, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 石田 裕嵩, 山内 拓郎, 加藤 伸史, 亀井 尚

    外科と代謝・栄養　56　(3)　85-85　2022/06

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  158. 食道癌周術期における亜鉛欠乏の臨床的意義

    山内 拓郎, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 福富 俊明, 小澤 洋平, 石田 裕嵩, 小関 健, 赤石 隆二郎, 堀江 悠太, 加藤 伸史, 亀井 尚

    外科と代謝・栄養　56　(3)　93-93　2022/06

    Publisher: 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  159. 非転移性褐色細胞腫におけるvascular endothelial growth factorsの検討

    阿部 一朗, Islam Farhadul, 石田 裕嵩, 小林 邦久, Lam Alfred

    日本内分泌学会雑誌　97　(5)　1602-1602　2022/03

    Publisher: (一社)日本内分泌学会

    ISSN： 0029-0661

    eISSN： 2186-506X

  160. 急速な増大を示した胸壁desmoplastic fibroblastomaの非常に稀な1例

    太田 英樹, 石田 裕嵩, 松本 秀一, 神宮 彰

    日本胸部外科学会定期学術集会　74回　LOD16-2　2021/10

    Publisher: (一社)日本胸部外科学会

  161. 食道扁平上皮癌におけるTXNRD1とHO-1発現と術前化学放射線療法抵抗性についての関連

    赤石 隆二郎, 藤島 史喜, 石田 裕嵩, 福富 俊明, 岡本 宏史, 高屋 快, 佐藤 千晃, 谷山 裕亮, 海野 倫明, 亀井 尚, 笹野 公伸

    日本外科学会定期学術集会抄録集　121回　PS-2　2021/04

    Publisher: (一社)日本外科学会

  162. 機能性食道疾患～診断と治療の進歩～ Sigmoid typeの食道アカラシアに対する内視鏡的筋層切開術(POEM)の治療成績

    丸山 祥太, 佐藤 千晃, 櫻井 直, 小関 健, 小野寺 優, 石田 裕嵩, 岡本 宏史, 瓶子 隆弘, 谷山 裕亮, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　72回　40-40　2018/06

    Publisher: (NPO)日本食道学会

  163. 次世代内視鏡の診断と治療～レーザー内視鏡とPDD/PDTの進歩～ 食道癌化学放射線療法後の局所遺残再発病変に対する光線力学療法(PDT)を導入して

    佐藤 千晃, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 岡本 宏史, 丸山 祥太, 小野寺 優, 石田 裕嵩, 伊東 賢, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　72回　47-47　2018/06

    Publisher: (NPO)日本食道学会

  164. 当科における胸腔鏡下食道切除術を執刀するまでのトレーニング法について

    伊東 賢, 小野寺 優, 石田 裕嵩, 丸山 祥太, 岡本 宏史, 佐藤 千晃, 瓶子 隆弘, 櫻井 直, 谷山 裕亮, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　72回　124-124　2018/06

    Publisher: (NPO)日本食道学会

  165. Barrett食道癌に対するリンパ節郭清範囲と術式の検討

    郷右近 祐介, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 丸山 祥太, 岡本 宏史, 石田 裕嵩, 小野寺 優, 内藤 剛, 亀井 尚, 海野 倫明

    日本外科学会定期学術集会抄録集　118回　1098-1098　2018/04

    Publisher: (一社)日本外科学会

  166. 食道胃接合部癌の縦隔リンパ節至適郭清範囲に対する検討

    瓶子 隆弘, 小野寺 優, 石田 裕嵩, 丸山 祥太, 櫻井 直, 谷山 裕亮, 内藤 剛, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　118回　1961-1961　2018/04

    Publisher: (一社)日本外科学会

  167. cT4食道癌に対する化学放射線治療後の外科手術の治療成績

    小野寺 優, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 佐藤 千晃, 丸山 祥太, 石田 裕嵩, 石田 孝宣, 内藤 剛, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　118回　2324-2324　2018/04

    Publisher: (一社)日本外科学会

  168. Barrett食道癌に対するリンパ節郭清範囲と術式の検討

    郷右近 祐介, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 丸山 祥太, 岡本 宏史, 石田 裕嵩, 小野寺 優, 内藤 剛, 亀井 尚, 海野 倫明

    日本外科学会定期学術集会抄録集　118回　1098-1098　2018/04

    Publisher: (一社)日本外科学会

  169. 食道胃接合部癌の縦隔リンパ節至適郭清範囲に対する検討

    瓶子 隆弘, 小野寺 優, 石田 裕嵩, 丸山 祥太, 櫻井 直, 谷山 裕亮, 内藤 剛, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　118回　1961-1961　2018/04

    Publisher: (一社)日本外科学会

  170. 金ナノ粒子を用いたがん転移リンパ節への光熱療法の開発

    及川 隆洋, 権田 幸祐, 高野 真由美, 猪瀬 智也, 徳永 正之, 北村 成史, 小林 芳男, 鳩山 恵一朗, 小野寺 優, 石田 裕嵩, 丸山 祥太, 佐藤 千晃, 濱田 庸, 瓶子 隆弘, 櫻井 直, 谷山 裕亮, 亀井 尚

    日本外科学会定期学術集会抄録集　118回　2119-2119　2018/04

    Publisher: (一社)日本外科学会

  171. cT4食道癌に対する化学放射線治療後の外科手術の治療成績

    小野寺 優, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 佐藤 千晃, 丸山 祥太, 石田 裕嵩, 石田 孝宣, 内藤 剛, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　118回　2324-2324　2018/04

    Publisher: (一社)日本外科学会

  172. 高難度症例への挑戦(胸腔) 高難度症例に対する胸腔鏡下食道癌手術 安全な胸腔鏡下サルベージ食道切除術の戦略とその手技の応用

    亀井 尚, 櫻井 直, 谷山 裕亮, 瓶子 隆弘, 佐藤 千晃, 岡本 宏史, 丸山 祥太, 小野寺 優, 石田 裕嵩, 今野 裕司

    日本内視鏡外科学会雑誌　22　(7)　VW2-3　2017/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  173. 高齢者食道癌に対する腹臥位胸腔鏡下食道切除術の検討 側臥位との比較

    岡本 宏史, 谷山 裕亮, 櫻井 直, 佐藤 千晃, 丸山 祥太, 石田 裕嵩, 小野寺 優, 内藤 剛, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　22　(7)　EP148-07　2017/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  174. High-riding innominate arteryを伴う食道癌に対しNerve Integrity Monitorを用い反回神経を温存しえた1例

    堀江 悠太, 石田 裕嵩, 小野寺 優, 丸山 祥太, 岡本 宏史, 佐藤 千晃, 櫻井 直, 谷山 裕亮, 内藤 剛, 海野 倫明, 亀井 尚

    日本内視鏡外科学会雑誌　22　(7)　EP193-07　2017/12

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  175. 開胸開腹手術での起死回生の一手(食道) 食道切除後、気道壊死に対する有茎性大網充填術の有用性

    櫻井 直, 谷山 裕亮, 瓶子 隆弘, 佐藤 千晃, 岡本 宏史, 丸山 祥太, 石田 裕嵩, 小野寺 優, 内藤 剛, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　78　(増刊)　339-339　2017/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  176. 内視鏡下手術での起死回生の一手(食道) 腹臥位胸腔鏡下食道切除術における左下肺静脈損傷のピットフォールと対応・予防策

    谷山 裕亮, 桜井 直, 瓶子 隆弘, 佐藤 千晃, 岡本 宏史, 丸山 祥太, 小野寺 優, 石田 裕嵩, 内藤 剛, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　78　(増刊)　344-344　2017/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  177. 食道・胃癌術前補助療法CR症例[手術vs経過観察] 食道癌術前補助療法Clinical Complete Response(CR)判定の適中率の検討

    瓶子 隆弘, 小野寺 優, 石田 裕嵩, 丸山 祥太, 岡本 宏史, 佐藤 千晃, 櫻井 直, 谷山 裕亮, 内藤 剛, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　78　(増刊)　355-355　2017/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  178. 食道癌補助療法後の至適郭清[3領域vs2領域] 術前化学療法後食道癌手術における頸部郭清の意義についての検討

    岡本 宏史, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 佐藤 千晃, 丸山 祥太, 石田 裕嵩, 小野寺 優, 内藤 剛, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　78　(増刊)　372-372　2017/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  179. 当科における胸腔鏡下食道切除術の手術手技と治療成績

    櫻井 直, 谷山 裕亮, 瓶子 隆弘, 佐藤 千晃, 岡本 宏史, 丸山 祥太, 小野寺 優, 石田 裕嵩, 内藤 剛, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　78　(増刊)　485-485　2017/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  180. Salvage食道切除術における安全性の追求 16年103例の経験から

    谷山 裕亮, 桜井 直, 瓶子 隆弘, 佐藤 千晃, 岡本 宏史, 丸山 祥太, 小野寺 優, 石田 裕嵩, 内藤 剛, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　78　(増刊)　514-514　2017/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  181. 食道破裂が疑われた食道裂孔ヘルニアを伴う胃潰瘍穿孔の一例

    小野寺 優, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 佐藤 千晃, 岡本 宏史, 丸山 祥太, 石田 裕嵩, 内藤 剛, 海野 倫明, 亀井 尚

    日本臨床外科学会雑誌　78　(増刊)　782-782　2017/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  182. 食道小細胞癌と類基底細胞癌の鑑別診断における免疫組織化学的特性と予後の検討

    石田 裕嵩, 笠島 敦子, 中野 徹, 谷山 裕亮, 櫻井 直, 武山 大輔, 佐藤 千晃, 藤島 史喜, 亀井 尚, 笹野 公伸

    日本消化器外科学会総会　72回　RS1-1　2017/07

    Publisher: (一社)日本消化器外科学会

  183. 食道小細胞癌の生検検体による正診率向上を目指して p16高発現とp40陰性を用いて

    石田 裕嵩, 武山 大輔, 中野 徹, 藤島 史喜, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 丸山 祥太, 小澤 洋平, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　71回　P44-5　2017/06

    Publisher: (NPO)日本食道学会

  184. Stage4乳癌患者に異時性に生じた進行性食道癌に対し根治切除術を施行した一例

    郷右近 祐介, 桜井 直, 中野 徹, 谷山 裕亮, 瓶子 隆弘, 武山 大輔, 石田 裕嵩, 藤島 史喜, 笹野 公伸, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　71回　P65-2　2017/06

    Publisher: (NPO)日本食道学会

  185. 食道に発生する神経内分泌腫瘍 食道小細胞癌の臨床病理学および免疫組織学的特性

    石田 裕嵩, 亀井 尚, 笠島 敦子, 神谷 蔵人, 久保田 洋介, 佐藤 千晃, 武山 大輔, 瓶子 隆弘, 櫻井 直, 谷山 裕亮, 藤島 史喜, 中野 徹, 笹野 公伸, 大内 憲明

    日本外科学会定期学術集会抄録集　117回　SF-8　2017/04

    Publisher: (一社)日本外科学会

  186. 食道癌におけるCT Perfusionを用いたヒストグラム解析による腫瘍血流評価と臨床応用の検討

    小野寺 優, 松浦 智徳, 亀井 尚, 中野 徹, 谷山 裕亮, 櫻井 直, 武山 大輔, 藤島 史喜, 石田 裕嵩, 大内 憲明

    日本外科学会定期学術集会抄録集　117回　PS-2　2017/04

    Publisher: (一社)日本外科学会

  187. 進行食道癌に浸潤する制御性T細胞の予後予測因子としての検討

    今野 卓朗, 藤島 史喜, 亀井 尚, 中村 保宏, 中野 徹, 櫻井 直, 伊東 賢, 石田 裕嵩, 笹野 公伸, 大内 憲明

    日本外科学会定期学術集会抄録集　117回　PS-6　2017/04

    Publisher: (一社)日本外科学会

  188. 食道扁平上皮癌における術前化学療法治療効果予測としてのMurine double minute 2の重要性

    伊東 賢, 藤島 史喜, 石田 裕嵩, 今野 卓郎, 亀井 尚, 笹野 公伸, 大内 憲明

    日本外科学会定期学術集会抄録集　117回　PS-6　2017/04

    Publisher: (一社)日本外科学会

  189. 食道小細胞癌におけるp16発現と治療法に関する後ろ向き研究

    石田 裕嵩, 中野 徹, 藤島 史喜, 谷山 裕亮, 櫻井 直, 佐藤 千晃, 小澤 洋平, 高橋 雅信, 神宮 啓一, 亀井 尚

    日本食道学会学術集会プログラム・抄録集　70回　116-116　2016/07

    Publisher: (NPO)日本食道学会

  190. 原発巣と転移巣の比較から考える食道癌のPD-L1発現と化学療法の感受性に関する検討

    今野 卓朗, 藤島 史喜, 石田 裕嵩, 伊東 賢, 小澤 洋平, 中村 保宏, 中野 徹, 亀井 尚, 笹野 公伸, 大内 憲明

    日本食道学会学術集会プログラム・抄録集　70回　176-176　2016/07

    Publisher: (NPO)日本食道学会

  191. 食道小細胞癌の臨床病理学的因子と治療に関する後ろ向き研究

    石田 裕嵩, 笠島 敦子, 亀井 尚, 藤島 史喜, 小澤 洋平, 中野 徹, 田中 洋一, 黒住 昌史, 笹野 公伸, 大内 憲明

    日本消化器外科学会総会　71回　P2-10　2016/07

    Publisher: (一社)日本消化器外科学会

  192. 食道小細胞癌の免疫組織学的特性と胎児食道との比較

    石田 裕嵩, 笠島 敦子, 亀井 尚, 三浦 豪, 藤島 史喜, 小澤 洋平, 中村 保宏, 田中 洋一, 黒住 昌史, 笹野 公伸

    日本病理学会会誌　105　(1)　406-406　2016/04

    Publisher: (一社)日本病理学会

    ISSN： 0300-9181

  193. 5-フルオロウラシル+シスプラチン併用食道癌術前化学療法におけるMurine double minute 2の重要性

    伊東 賢, 藤島 史喜, 亀井 尚, 石田 裕嵩, 今野 卓朗, 伊勢 和恵, 端 秀子, 中村 保宏, 大内 憲明, 笹野 公伸

    日本病理学会会誌　105　(1)　490-490　2016/04

    Publisher: (一社)日本病理学会

    ISSN： 0300-9181

  194. 前加療後切除した食道類基底細胞癌4症例と術前未治療21症例との臨床病理組織学的比較

    今野 卓朗, 亀井 尚, 中野 徹, 阿部 薫夫, 藤島 史喜, 小澤 洋平, 伊東 賢, 石田 裕嵩, 笹野 公伸, 大内 憲明

    日本食道学会学術集会プログラム・抄録集　69回　166-166　2015/07

    Publisher: (NPO)日本食道学会

  195. 食道扁平上皮癌細胞におけるc-Met分子の発現と分子標的治療のターゲットとしての有用性の検討

    小澤 洋平, 中村 保宏, 藤島 史喜, 岡本 宏史, 伊東 賢, 石田 裕嵩, 今野 卓朗, 亀井 尚, 大内 憲明, 笹野 公伸

    日本消化器外科学会総会　70回　P-5　2015/07

    Publisher: (一社)日本消化器外科学会

  196. 摘出食道全長におよぶLong Segment Barrett Esophagusに発生したBarrett腺癌の1例

    伊東 賢, 藤島 史喜, 今野 卓郎, 石田 裕嵩, 小澤 洋平, 亀井 尚, 宮田 剛, 大内 憲明, 笹野 公伸

    日本臨床外科学会雑誌　75　(増刊)　740-740　2014/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  197. 術前に扁平上皮癌と診断され術前化学療法を施行した食道癌肉腫の1例

    石田 裕嵩, 谷山 裕亮, 日景 允, 手島 仁, 桂 一憲, 櫻井 直, 阿部 薫夫, 中野 徹, 亀井 尚, 宮田 剛

    日本食道学会学術集会プログラム・抄録集　68回　199-199　2014/07

    Publisher: (NPO)日本食道学会

  198. 細胞転写法にて最終診断が可能であった腸型肺腺癌と下行結腸癌を重複した一例

    鈴木 由佳, 遠藤 悦子, 横田 憲一, 石田 裕嵩, 村山 優理香, 三浦 弘守, 笹野 公伸

    日本臨床細胞学会雑誌　52　(Suppl.2)　639-639　2013/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  199. 癌性リンパ管症にて発症するも18ヵ月の生存を得た腸型肺腺癌の1例

    石田 裕嵩, 横田 憲一, 笹野 公伸

    日本癌治療学会誌　48　(3)　2410-2410　2013/09

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  200. 初回手術から13年経過し後腹膜に発生した異時性多発性の脱分化型巨大脂肪肉腫の1例

    石田 裕嵩, 横田 憲一, 横山 成邦, 大友 浩志, 笹野 公伸

    日本消化器外科学会総会　68回　P-7　2013/07

    Publisher: (一社)日本消化器外科学会

  201. 食道癌術後で横隔膜ヘルニアにより絞扼性イレウスをきたした1例

    石田 裕嵩, 横山 成邦, 横田 憲一

    日本臨床外科学会雑誌　73　(増刊)　712-712　2012/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

    eISSN： 1882-5133

  202. 長期生存が得られた結腸癌・異時性孤立性副腎転移の1切除例

    福島 啓介, 横田 憲一, 大友 浩志, 板倉 裕子, 横山 成邦, 石田 裕嵩, 遠藤 渉

    日本消化器外科学会雑誌　45　(Suppl.2)　440-440　2012/10

    Publisher: (一社)日本消化器外科学会

    ISSN： 0386-9768

    eISSN： 1348-9372

  203. 胆石症術前精査を契機に発見された虫垂粘液嚢胞腺腫の一例

    乗田 一明, 涌井 祐太, 李 宇鐘, 國吉 真平, 石橋 信之, 相澤 宏樹, 小松 正歩, 星 達也, 笠沼 勇一, 鈴木 忠泰, 安海 清, 石田 裕嵩, 岩根 尊, 笹野 公伸

    Gastroenterological Endoscopy　54　(Suppl.2)　2932-2932　2012/09

    Publisher: (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  204. 当科における過去15年間の食道癌手術成績

    横山 成邦, 石田 裕嵩, 福島 啓介, 板倉 裕子, 大友 浩志, 横田 憲一, 遠藤 渉

    日本消化器外科学会総会　67回　1-1　2012/07

    Publisher: (一社)日本消化器外科学会

  205. CT撮影により偶然に発見された膵原発非機能性ソマトスタチン産生腫瘍の1例

    石田 裕嵩, 板倉 裕子, 福島 啓介, 横山 成邦, 大友 浩志, 横田 憲一, 遠藤 渉, 笹野 公伸

    日本消化器外科学会総会　67回　2-2　2012/07

    Publisher: (一社)日本消化器外科学会

Show all ︎Show first 5

Presentations 56

  1. ロボット支援手術時代における若手食道外科医の育成 ～開胸、胸腔鏡、そしてロボット支援手術へ～

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 亀井 尚

    第79回日本胸部外科学会定期学術集会　2026/10/21

  2. Investigation of Specific Complications in Robot-Assisted Minimally Invasive Esophagectomy

    Hirotaka Ishida, Yusuke Taniyama, Chiaki Sato, Hiroshi Okamoto, Yohei Ozawa, Naoto Ujiie, Shinobu Ohnuma, Michiaki Unnno, Takashi Kamei

    The 39th Japan Society for Endoscopic Surgery/WCES 2026　2026/09/02

  3. 食道癌患者の術前DCF療法における 生体電気インピーダンス法を用いた体組成指標と有害事象の関連

    石田裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤洋平, 氏家 直人, 押切 裕之, 亀井 尚

    日本外科代謝栄養学会第63回学術集会　2026/07/31

  4. 食道癌術後早期の全身性炎症と再発リスクの検討 ～プロカルシトニンとCRPの差異～

    石田裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤洋平, 氏家 直人, 海野 倫明, 亀井 尚

    第32回侵襲とサイトカイン研究会　2026/07/30

  5. 食道扁平上皮癌根治切除後のオリゴ転移に対する ICIを含めた治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 押切 裕之, 亀井 尚

    第80回日本食道学会学術集会　2026/06/26

  6. 食道吊り上げ時の工夫 Invited

    石田 裕嵩

    第14回東北食道外科セミナー　2026/06/24

  7. ロボット支援下食道切除術における特有トラブルの検討 ～触覚フィードバックを欠く手術の落とし穴と対策～

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 大沼 忍, 海野 倫明, 亀井 尚

    第37回内視鏡外科フォーラム　2026/05/09

  8. ロボット支援食道切除を担う次世代外科医のための新たな体系的教育

    石田 裕嵩, 佐藤 千晃, 岡本 宏史, 氏家 直人, 海野 倫明, 亀井 尚

    第112回日本消化器病学会総会　2026/04/18

  9. 食道アカラシア治療における継往開来

    石田 裕嵩, 佐藤 千晃, 岡本 宏史, 氏家 直人, 安藤 涼平, 海野 倫明, 亀井 尚

    日本消化器病学会東北支部第220回例会　2026/02/07

  10. 開胸、胸腔鏡、そしてロボット支援食道切除の修得のための若手手術教育

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 大沼 忍, 海野 倫明, 亀井 尚

    第38回日本内視鏡外科学会総会　2025/12/11

  11. 食道アカラシア関連疾患と混合型食道裂孔ヘルニアを合併した一例

    石田 裕嵩, 佐藤 千晃, 安藤 涼平, 邑並 佑人, 亀井 尚

    第3回Japan Foregut Society 学術研究会　2025/11/15

  12. 胸腔鏡からロボット支援食道切除への若手教育の取組みと課題

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 大沼 忍, 海野 倫明, 亀井 尚

    JDDW 2025　2025/10/31

  13. 当科における胃管再建の術中～術後管理における工夫/消化管 再建に難渋した症例

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 亀井 尚

    第78回日本胸部外科学会定期学術集会　2025/10/25

  14. Treatment Strategies and Long-term Outcomes for Patients with Oligometastasis in Esophageal Squamous Cell Carcinoma after Radical Esophagectomy

    2025/09/19

  15. 大動脈食道瘻の治療戦略 ～領域横断・高難度手術の定型化～

    石田 裕嵩, 谷山 裕亮, 鈴木 佑輔, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 齋木 佳克, 亀井 尚

    第2回 JATS-NEXT Annual Conference　2025/08/30

  16. JATS-NEXT世代のコーチングが組織にもたらす影響

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 氏家 直人, 佐々木 郁, 亀井 尚

    第2回JATS-NEXT Annual Conference　2025/08/30

  17. 食道癌根治切除後のOligometastasis症例に対する治療戦略の検討

    石田裕嵩, 谷山裕亮, 佐藤千晃, 岡本宏史, 小澤洋平, 安藤涼平, 大沼忍, 海野倫明, 亀井尚

    第80回日本消化器外科学会総会　2025/07/16

  18. 食道扁平上皮癌根治切除後のOligometastasis症例に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 篠﨑 康晴, 亀井 尚

    第79回日本食道学会学術集会　2025/06/27

  19. レーザードップラー血流計/酸素飽和度イメージングを 用いた胃管評価の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 高橋 洵, 亀井 尚

    第79回日本食道学会学術集会　2025/06/26

  20. 食道アカラシア・シグモイド型に対するPOEMの治療成績

    石田 裕嵩, 佐藤 千晃, 安藤 涼平, 邑並 祐人, 丸山 大貴

    第109回日本消化器内視鏡学会総会　2025/05/09

  21. 76歳以上の高齢食道扁平上皮癌患者への NAC施行の意義の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 篠﨑 康晴, 大沼 忍, 海野 倫明, 亀井 尚

    第125回日本外科学会学術集会　2025/04/12

  22. 食道アカラシアに対する 経口内視鏡的筋層切開術(POEM) ～導入と治療成績～

    石田 裕嵩, 佐藤 千晃, 安藤 涼平

    第173回日本消化器内視鏡学会東北支部例会　2025/02/07

  23. 食道切除術における酸素飽和度イメージングを 用いた再建臓器評価

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 高橋 洵, 海野 倫明, 亀井 尚

    第37回日本内視鏡外科学会総会　2024/12/07

  24. ビデオクリニック Invited

    石田 裕嵩

    第13回食道平成2桁の会　2024/12/06

  25. 低侵襲食道切除後における血中CRP/PCT濃度の縫合不全診断マーカーとしての意義

    石田 裕嵩、谷山 裕亮、佐藤 千晃、岡本 宏史、小澤 洋平、亀井 尚

    第77回日本胸部外科学会定期学術集会　2024/11/03

  26. 80歳以上の高齢者食道切除の短期/長期成績の検討

    石田 裕嵩, 谷山 裕亮, 亀井 尚

    JDDW 2024　2024/11/02

  27. 低侵襲食道切除後における血中CRP濃度の炎症/予後予測マーカーとしての意義

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤洋平, 安藤 涼平, 篠﨑 康晴, 亀井 尚

    第61回日本外科代謝栄養学会学術集会　2024/07/26

  28. 低侵襲食道切除後・プロカルシトニンの感染性合併症/予後予測マーカーとしての意義

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤洋平, 安藤 涼平, 篠﨑 康晴, 亀井 尚

    第30回侵襲とサイトカイン研究会　2024/07/25

  29. 当科における食道胃接合部癌の現状と治療成績の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤洋平, 安藤 涼平, 篠﨑 康晴, 海野 倫明, 亀井 尚

    第79回日本消化器外科学会総会　2024/07/17

  30. 食道癌根治切除後のOligometastasis症例に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 安藤 涼平, 篠﨑 康晴, 亀井 尚

    第78回日本食道学会学術集会　2024/07/04

  31. プロテインＣ/Ｓ欠乏症を伴う食道手術のピットフォール Invited

    石田 裕嵩

    第12回東北食道外科セミナー　2024/07/04

  32. 私の留学先の見つけ方 ～Griffith University (＠Gold Coast, Australia)～

    石田 裕嵩

    第1回 JATS-NEXT Annual Conference　2024/01/27

  33. 食道癌根治切除後のOligometastasis症例に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 加藤 伸史, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 大沼 忍, 海野 倫明, 亀井 尚

    第85回日本臨床外科学会総会　2023/11/18

  34. 当科における食道癌根治切除後・術野内再発の検討

    石田 裕嵩, 谷山 裕亮, 佐藤 千晃, 岡本 宏史, 小澤 洋平, 亀井 尚

    第76回日本胸部外科学会定期学術集会　2023/10/20

  35. Therapeutic strategy for patients with oligometastasis of esophageal cancer after radical surgery

    Hirotaka Ishida, Yusuke Taniyama, Nobufumi Kato, Yohei Ozawa, Hiroshi Okamoto, Chiaki Sato, Shinobu Ohnuma, Michiaki Unno, Takashi Kamei

    2023/07/13

  36. cStage IIIB/IVA食道癌に対する治療戦略の検討

    石田 裕嵩, 谷山 裕亮, 佐藤, 千晃, 岡本 宏史, 小澤 洋平, 小関, 健 亀井 尚

    第77回日本食道学会学術集会　2023/06/29

  37. 当科の低侵襲食道癌手術における術者育成と術後成績の検討

    石田 裕嵩, 谷山 裕亮, 山内 拓郎, 加藤, 伸史, 小関 健, 小澤 洋平, 岡本, 宏史, 佐藤 千晃, 大沼 忍, 海野, 倫明, 亀井 尚

    第35回日本内視鏡外科学会総会　2022/12/09

  38. A diagnostic pitfall; small cell carcinoma-like features in basaloid squamous cell carcinoma of the esophagus

    Hirotaka Ishida, Atsuko Kasajima, Takuro Yamauchi, Nobufumi Kato, Ken Koseki, Yohei Ozawa, Hiroshi Okamoto, Chiaki Sato, Yusuke Taniyama, Fumiyoshi Fujishima, Takashi Kamei, Hironobu Sasano

    2022/09

  39. 食道類基底細胞癌の生検検体における 小細胞癌様所見の臨床病理学的意義

    石田 裕嵩, 笠島 敦子, 小関 健, 小澤 洋平, 岡本 宏史, 佐藤 千晃, 谷山 裕亮, 藤島 史喜, 亀井 尚, 笹野 公伸

    第76回日本食道学会学術集会　2022/09

  40. 食道小細胞癌の病理組織学的特性 ～生検検体による正診率向上を目指して～

    石田 裕嵩, 笠島 敦子, 藤島 史喜, 山﨑 有人, 三浦 豪, 中村 保宏, 田中 洋一, 黒住 昌史, 小池 智幸, 下瀬川 徹, 亀井 尚, 笹野 公伸

    第5回日本神経内分泌腫瘍研究会学術集会　2017/09/02

  41. 食道粘膜下腫瘍の術前診断と術式選択の検討および新たな手技について

    石田 裕嵩, 谷山 裕亮, 小野寺 優, 岡本 宏史, 亀井 尚

    第70回日本胸部外科学会定期学術集会　2017/09

  42. 食道小細胞癌と類基底細胞癌の鑑別診断における免疫組織化学的特性と予後の検討

    石田 裕嵩, 笠島 敦子, 中野 徹, 谷山 裕亮, 櫻井 直, 武山 大輔, 佐藤 千晃, 藤島 史喜, 亀井 尚, 笹野 公伸

    第72回日本消化器外科学会総会　2017/07

  43. 食道小細胞癌の生検検体による正診率向上を目指して～p16高発現とp40陰性を用いて～

    石田 裕嵩, 武山 大輔, 中野 徹, 藤島 史喜, 谷山 裕亮, 櫻井 直, 瓶子 隆弘, 丸山 祥太, 小澤 洋平, 亀井 尚

    第71回日本食道学会学術集会　2017/06

  44. 食道に発生する神経内分泌腫瘍 食道小細胞癌の臨床病理学および免疫組織学的特性.

    石田 裕嵩, 亀井 尚, 笠島 敦子, 神谷 蔵人, 久保田 洋介, 佐藤 千晃, 武山 大輔, 瓶子 隆弘, 櫻井 直, 谷山 裕亮, 藤島 史喜, 中野 徹, 笹野 公伸, 大内 憲明

    第117回日本外科学会定期学術集会　2017/04

  45. 食道および肺小細胞癌に共通する免疫組織学的な腺上皮分化

    石田 裕嵩, 笠島 敦子, 亀井 尚, 岡 直美, サマネ・ヤズダニキビ, 藤島 史喜, 桜田 晃, 中村 保宏, 田中 洋一, 黒住 昌史, 石川 雄一, 岡田 克典, 大内 憲明, 笹野 公伸

    第4回日本神経内分泌腫瘍研究会学術集会　2016/09/24

  46. Clinicopathological and immunohistochemical characteristics of esophageal small cell carcinoma: A comparison study.

    Hirotaka Ishida, Kasajima A., Kamei T., Fujishima F., Konno T., Ito K., Ozawa Y., Nakano T., Nakamura Y., Tanaka Y., Kurosumi Y., Ohuchi N., Sasano H.

    15th ISDE World Congress of Esophageal Disease　2016/09

  47. 食道小細胞癌におけるp16発現と治療法に関する後ろ向き研究

    石田 裕嵩, 中野 徹, 藤島 史喜, 谷山 裕亮, 櫻井 直, 佐藤 千晃, 小澤 洋平, 高橋 雅信, 神宮 啓一, 亀井 尚

    第70回日本食道学会学術集会　2016/07

  48. 食道小細胞癌の臨床病理学的因子と治療に関する後ろ向き研究

    石田 裕嵩, 笠島 敦子, 亀井 尚, 藤島 史喜, 小澤 洋平, 中野 徹, 田中 洋一, 黒住 昌史, 笹野 公伸, 大内 憲明

    第71回日本消化器外科学会総会　2016/07

  49. 食道小細胞癌の免疫組織学的特性と胎児食道との比較

    石田 裕嵩, 笠島 敦子, 亀井 尚, 三浦 豪, 藤島 史喜, 小澤 洋平, 中村 保宏, 田中 洋一, 黒住 昌史, 笹野 公伸

    第105回日本病理学会総会　2016/05

  50. 食道小細胞癌におけるSOX2過剰発現と免疫組織学的特性

    石田 裕嵩, 笠島 敦子, 三浦 豪, 藤島 史喜, 今野 卓朗, 伊東 賢, 小澤 洋平, 中村 保宏, 亀井 尚, 田中 洋一, 黒住 昌史, 田久保 海誉, 大内 憲明, 笹野 公伸

    第3回日本神経内分泌腫瘍研究会学術集会　2015/09/12

  51. Surgical resection and chemoradiotherapy for metachronous pulmonary metastasis of basaloid squamous cell carcinoma of the esophagus.

    Hirotaka Ishida, Nakano T., Okamoto H., Fujishima F., Kamei T., Miyata G., Sasano H., Ohuchi N.

    14th ISDE World Congress of Esophageal Disease　2014/09

  52. 術前に扁平上皮癌と診断され術前化学療法を施行した食道癌肉腫の1例

    石田 裕嵩, 谷山 裕亮, 日景 允, 手島 仁, 桂 一憲, 櫻井 直, 阿部 薫夫, 中野 徹, 亀井 尚, 宮田 剛

    第68回日本食道学会学術集会　2014/07

  53. 癌性リンパ管症にて発症するも18ヵ月の生存を得た腸型肺腺癌の1例

    石田 裕嵩, 横田 憲一, 笹野 公伸

    第51回日本癌治療学会学術集会　2013/10

  54. 初回手術から13年経過し後腹膜に発生した異時性多発性の脱分化型巨大脂肪肉腫の1例

    石田 裕嵩, 横田 憲一, 横山 成邦, 大友 浩志, 笹野 公伸

    第68回日本消化器外科学会総会　2013/07

  55. 食道癌術後で横隔膜ヘルニアにより絞扼性イレウスをきたした1例

    石田 裕嵩, 横山 成邦, 横田 憲一

    第74回日本臨床外科学会総会　2012/11

  56. CT撮影により偶然に発見された膵原発非機能性ソマトスタチン産生腫瘍の1例

    石田 裕嵩, 板倉 裕子, 福島 啓介, 横山 成邦, 大友 浩志, 横田 憲一, 遠藤 渉, 笹野 公伸

    第67回日本消化器外科学会総会　2012/07

Show all Show first 5

Research Projects 1

  1. 食道癌におけるヒトパピローマウイルス感染と化学放射線療法の感受性に関する研究

    石田 裕嵩

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業 若手研究

    Category: 若手研究

    Institution: 東北大学

    2022/04/01 - 2025/03/31